Berczi
Gorczynski
Editors
|
| MENU
|
|
|
 |
Vol.1:New
Foundation of Biology
Volume
Editors:Istvan Berczi and Reginald M. Gorczynski |
|
New
Foundation of Biology
Edited
by I. Berczi and R. M. Gorczynski
©
2001 Elsevier Science B. V.
All
rights reserved
(Article
reprint used with permission, NIB 2001;1:3-45)
Neuroimmune
Biology — An Introduction
ISTVAN
BERCZI
Department
of Immunology, Faculty of Medicine, The University of Manitoba, Bannatyne
Campus, 31-795 McDermot Avenue, Winnipeg, Manitoba R3E 0W3, Canada
ABSTRACT
That a healthy mind is fundamental to general well being has been recognized
since prehistoric times and proverbs analogous to "Healthy body – healthy
mind" exist in many languages. A century ago pathologists noted first that
the size of the thymus was profoundly influenced by emotional events and
by neuroendocrine aberrations. Hans Selye discovered first (1936) that
the hypothalamus-pituitary-adrenal axis, which is activated by diverse
'nocuous' stimuli, leads to the rapid involution of the thymus. He coined
this phenomenon as the 'stress' response. Selye established that stress
results in the development of the general adaptation syndrome which is
characterized by elevated resistance to diverse insults. Andor Szentivanyi
and colleagues discovered (1949) that hypothalamic lesions prevent anaphylactic
death in guinea pigs. This is the first experimental evidence for the sweeping
regulatory power of the nervous system over violent, life threatening immune
reactions. That the nervous system also controls the inflammatory response
was first demonstrated by Miklos Jancso and co-workers (1964). These fundamental
discoveries were not followed by a burst of research activity. Progress
has been slow because of the lack of basic knowledge and because of the
immense technical difficulties encountered. In the seventies a handful
of laboratories started to re-examine various aspects of neuroimmune-interaction.
It was established that pituitary hormones have the capacity to stimulate,
inhibit and modulate immune responses. Placental and pituitary hormones
are also involved in the development of the immune system and maintenance
of immunocompetence. It was also described that lymphoid organs are innervated
and that neurotransmitters and neuro-peptides are important immunomodulators.
It became gradually apparent that immune derived cytokines and nerve impulses
serve as feedback signals towards the neuroendocrine system. Compelling
evidence was produced, indicating that immune reactions may be conditioned
in the classical pavlovian sense and that emotions affect immune function
of various organs and tissues, and in reproduction. It is also becoming
obvious that Selye's general adaptation syndrome really corresponds to
the acute phase response. This is a multi-faceted and highly co-ordinated
systemic defense reaction, which involves the conversion of the immune
system from a specific, adaptive mode of reactivity to a rapidly amplifiable
polyspecific reaction mediated by natural immune mechanisms. Immunological
(poly) specificity is assured by profoundly elevated levels of natural
antibodies and liver derived proteins.
Much has been learned about the regulation of cell activation, growth and
function from immunological studies. Burnet's clonal selectional theory
designates antigen as the sole activator. Bretcher and Cohn recognised
first that at least 2 signals are required. This was followed by numerous
studies on cell-to-cell interaction within the immune system and led to
our current understanding of the importance of cell adhesion molecules
and cytokines in cell activation and proliferation. This, couples with
the available information about the mechanisms of action of hormones and
neurotransmitters, of signal transduction and nuclear regulatory pathways
paves the way to understanding how higher organisms function in their entire
complexity. It is now apparent that the Nervous-Endocrine-and Immune-systems
form a systemic regulatory network, which is capable of regulating all
aspects of bodily functions in health and disease. Thus, Neuroimmune Biology
provides new foundations to Biology.
1.
INTRODUCTION
Observations indicating that the central nervous system has a fundamental
role in the maintenance of health has been made since prehistoric times
and is referred to in proverbs of many languages. The healing power of
mind and faith provides one of the important foundations of religion and
is described in many religious texts. These phenomena are also observed
in modern medicine and is known as the placebo effect. It has been demonstrated
repeatedly by exact scientific methodology that patients treated with placebo
in controlled medical trials do in fact show significant improvement clinically
in the absence of effective treatment. In ancient Persia, Egypt and in
the Roman Empire fever has been regarded as a reaction with healing power.
This view was maintained until modern times and during the early nineteen
hundreds pyrogenic substances have been developed for the purposes of fever
therapy [1-3].
About a century ago pathologists observed that acromegaly was frequently
associated with thymic hyperplasia. Hammar [4] described that the thymus
frequently showed involution under the influence of environmental or emotional
factors. In contrast, thymic hyperplasia was associated with castration,
Graves' Disease, Addison's Disease and acromegaly. Smith described in 1930
that in hyposectomyzed (Hypox) rats the thymus regressed in weight to less
than half of that of controls. In partially Hypox rats there was no involution
[5].
In 1936 Hans Selye documented that the pituitary-adrenal-thymus axis was
activated by various nocuous stimuli, which led to the involution of the
thymus and of the lymphoid organs [6, 7]. Moreover, Selye has established
that the bursa of Fabricius in chickens was extremely sensitive to steroid
hormones [8]. Within ten years Selye has proposed the theory of general
adaptation syndrome (GAS) [9] on the basis of his experiments. He pointed
out that this is a general reaction that leads to resistance of the organism
to various insults. Selye's scheme of GAS is shown in Figure 1, updated
with current information. In 1949 Selye discovered that the inflammatory
response is regulated by corticosteroids [10]. In his article entitled
"Stress and Disease" he proposed that deficient host defense due to abnormalities
of neuroendocrine factors may lead to disease [11]. Selye recognized the
importance of mast cells in pathology and performed numerous studies in
this respect. He summarized the knowledge about mast cell in a book [12],
which is a lasting contribution on the subject.
Page
5
 |
Figure
1: Functional interrelations during the general adaptation syndrome.
This figure is modified from Selye [9] by updating it with recent information.
Solid arrows and the two broken arrows on the top with bold text is Selye's
original figure. Recently identified pathways are indicated with dotted
arrows and with text in italics. The text below is also from Selye. "Schematized
drawing indicating that non-specific damage causes clinical shock, loss
of body weight and nitrogen, gastro-intestinal ulcers, temporary rise in
plasma potassium with fall in plasma Cl, through unknown pathways (nervous
stimulus?, deficiency?, toxic metabolites?) but manifestly not through
the stimulation of the hypophyseoadrenal mechanism. This is proven by the
fact that the above manifestations are not prevented either by hypophysectomy
or by adrenalectomy; they even tend to be more severe in the absence of
either or both of these glands.
Non-specific damage, again through unknown pathways, also acts upon the
hypophysis and causes it to increase corticotropic hormone production at
the expense of a decreased elaboration of gonadotropic, lactogenic and
growth hormones. The resulting corticotropic hormone excess causes enlargement
of the adrenal cortex with signs of increased corticoid hormone production.
These corticoids in turn cause changes in the carbohydrate (sugar active
corticoids) and electrolyte metabolism (salt-active corticoids) as well
as atrophy of the thymus and the other lymphatic organs. It is probable
that the cardiovascular, renal, blood pressure and arthritic changes are
secondary to the disturbances in electrolyte metabolism since their production
and prevention are largely dependent upon the salt intake. The changes
in g -globulin, on the other hand, appear to be secondary to the effect
of corticoids upon the thymicrolymphatic apparatus.
We do not know as yet, whether the hypertension is secondary to the nephrosclerosis
or whether it is a direct result of the disturbance in electrolyte metabolism
caused by the corticoids. Similarly, it is not quite clear, as yet, whether
corticoids destroy the circulating lymphocytes directly, or whether they
influence the lymphocyte count merely by diminishing lymphocyte formation
in the lymphatic organs. Probably both these mechanisms are operative". |
Page 6
Selye made all his contributions without knowing the function of the thymus,
lymph nodes or the bursa of Fabricius. The function of these organs was
understood in the sixties and early seventies, decades after he published
his seminal papers on stress. With the advent of the science of Immunology
it became clear that stress has a profound immunosuppressive effect and
increases the susceptibility to infectious disease. These findings seemed
to contradict Selye's conclusion that the response to stress was an adaptive
defense reaction which increased the resistance of the body to various
noxious agents.
Andor Szentivanyi and his colleagues were the first to document that the
nervous system has a dominant regulatory power over immune reactions. As
a medical student Szentivanyi observed that adrenaline treatment was ineffective
to alleviate an asthmatic attack in a patient. This clinical observation
inspired him to do experiments in guinea pigs using anaphylactic shock
as a model system. Hypothalamic lesions inhibited the development of anaphylactic
shock in immunized animals [13]. Tuberal lesions (TBL) of the hypothalamus
were effective in preimmunized guinea pigs and in later experiments also
in rabbits to inhibit anaphylactic reactions elicited by the intravenous
application of the antigen. Antibody production was also inhibited if the
lesions were induced prior to immunization. The reaction of antibodies
with the specific antigen was not affected by such lesions, nor was the
release of tissue material mediating anaphylaxis. TBL temporarily increased
the resistance of the animals to histamine and inhibited the anaphylactic
reaction even when the animals were provided with passively transferred
antibody, which elicited lethal shock in normal animals. The Schultz-Dale
test, which was performed with small pieces of intestine in vitro, was
also inhibited when the animals were subjected to TBL. The Arthus reaction,
turpentine induced inflammation and the Sanarelli-Schwartzmann phenomenon
were unaffected by hypothalamic lesions. Lesions inflicted in other areas
of the hypothalamus or the central nervous system were ineffective in modulating
immune phenomena. Electrical stimulation of the mamillary region of the
hypothalamus had an inhibitory effect on the anaphylactic response and
increased the resistance of animals to histamine [14-16].
Szentivanyi devoted his entire career to the study of allergy and asthma.
Animal experiments pointed to the importance of the beta-adrenergic receptor
in these reactions [17]. In 1968 Szentivanyi had synthesized the knowledge
and all his findings in a review article, entitled, "The beta-adrenergic
theory of the atopic abnormality in bronchial asthma" [18]. He concluded
that bronchial asthma, whether it is due to "extrinsic" or "intrinsic"
causes, is ultimately elicited by the same mediators, such as histamine,
serotonin, catecholamines, slow reactive substances plus cytokines. These
are released during asthmatic reactions and should be considered as additional
group of mediators in many tissues and in most species. Glucocorticoids
are natural inhibitors of inflammation. He proposed that the atopic abnormality
in asthma is due to the abnormal function of the beta-adrenergic system,
irrespective of what triggered the reaction:
"The beta adrenergic theory regards asthma not as an 'immunological disease'
but as a unique pattern of bronchial hypersensitivity to a broad spectrum
of immunological, psychic, infectious, chemical and physical stimuli. This
gives to the antigen-antibody interaction the same role as that of a broad
category of non-specific stimuli which function only to trigger the same
defective homeostatic mechanism in the various specialized cells of bronchial
tissue".
Szentivanyi remained faithful to the idea of beta-adrenergic malfunction
in atopy and asthma. This is the common thread that connects the numerous
papers reviews, book chapters and books he published. He studied alpha
and beta adrenergic receptors; adenylcyclase, cyclic-AMP and signal transduction;
isolated, characterized and pharmacologically modulated phosphodiesterase;
observed the systemic effect of immunization and of endotoxin on the adrenergic
and cholinergic systems, on metabolism and on immune inflammatory mediators;
performed clinical studies on asthma and related conditions.
Page
7
His
major observations were:
1.
|
Beta-adrenergic
sub-sensitivity did exist in patients with atopic dermatitis who never
received adrenergic medication. This indicates that therapeutic desensitization
cannot account for the dysfunction of the beta-adrenergic system [19]. |
2.
|
The
beta-adrenergic reactivity of lung tissue of lymphocytes and bronchocytes
from patients with atopic asthma was found to be abnormal and various patterns
of drug vs. disease-induced sub-sensitivity could be recognized [20-25]. |
3.
|
Bronchial
hyper-reactivity to cholinergic agents in asthma was not mediated through
cholinergic mechanisms but it was caused by the adrenergic abnormality,
which was due to the so called "denervation super-sensitivity" [26-29]. |
4.
|
Lymphocytes
of asthmatic patients showed a significant decrease in adrenaline
binding
to beta-adrenergic receptors, which was independent of therapy [21, 22,
25].
Szentivanyi
also studied the effects of inflammation on b-adrenergic
receptors [30-33]. |
In 1964 Korneva and Khai [34] described that hypothalamic lesions in commonly
used laboratory rodents (e. g. rabbits, guinea pigs, rats) inhibited the
production of complement fixing antibodies.
In 1949 Miklos Jancso and co-workers reported that capsaicin is a sensory
irritant and that repeated local or systemic administration to rats, mice
and guinea pigs causes desensitization, which involves interference with
pain receptors. Systemic pretreatment of animals with capsaicin or repeated
local applications prevented the inflammatory response, indicating the
involvement of the nervous system. This was later confirmed by experiments
performed on denervated tissues. These observations indicated the existence
of a distinct form of inflammation, which depends on sensory nerve innervation.
The stimulation of C-fibers was necessary to induce this inflammatory response.
The neurogenic inflammatory response was also demonstrated in man [35,
36].
It was known for some time that hormones, including those secreted by the
pituitary gland, affect immune reactions [37]. However, only after the
publication of systematic studies performed on hypophysectomized rats and
in animals treated with bromocriptine [38-42], was the role of pituitary
hormones seriously considered in immunoregulation by the scientific community.
In 1975 Wannemacker and co-workers isolated the leukocyte endogenous mediator
(LEM) of fever [43], which was the first immune-derived molecule identified,
that mediated feedback signals towards the central nervous system. Later
LEM was found to be identical with interleukin-1. That IL-1 also serves
as a signal for pituitary hormone release was shown by a number of investigators
in the early 1980's [44-49]. Subsequently other cytokines, especially IL2,
IL6, TNF-alpha and interferon gamma were shown to regulate the secretion
of pituitary hormones during systemic immune/inflammatory reactions [50].
It is also clear by now that the nerves have immunoregulatory function
and provide feedback signals from lymphoid organs and from sites of immune/inflammatory
reactions towards the central nervous system (CNS) [51-54].
In 1926 Metalnikov and Chorine proposed first the behavioral modification
of the immune response [55]. In 1933 Smith and Salinger [56] observed that
asthmatic attacks were provoked in some patients with visual stimuli in
the absence of the allergen. That immune reactions can be conditioned in
the Pavlovian sense was demonstrated by Ader, MacQueen et al and by Gorczynski
et al [57-59]. It was also observed that various cells in the immune system
produce classical hormones and neurotransmitters. Smith and Blalock, Montgomery
et al and DiMathia et al. [60-62] pioneered these observations.
Page
8
NEUROIMMUNE
INTERACTIONS
2.1.
Cell-to-cell interaction
Traditionally the cells of all tissues and organs have been divided into
stromal cells, which were thought to provide for the structure of organs
and the frame for the functioning cells, which were called parenchymal
cells. It is now evident that stromal cells interact actively with parenchymal
elements and this interaction leads to functional regulation of the tissue/
organ. Moreover, invariably the stroma of all tissues and organs contain
immune derived elements such as lymphocytes, macrophages or more specialized
cells that include the glia cells in the nervous system, Kupffer cells
in the liver, the Langerhans cells in the skin, etc. These cells contribute
to function both in health and disease. Blood vessels and endothelial cells
lining the blood vessels are also active participants in lymphocyte recirculation
and in local immune/ inflammatory reactions. These cells interact both
with the circulatory elements of the immune system and locally with elements
of the tissue/ organ. Cell-to-cell regulation in tissues is mediated by
adhesion molecules that have complementary binding sites. These molecules
are capable of delivering activation or inhibitory signals in a tissue
and cell-specific manner [63-76].
Adhesion molecules and other cell membrane receptors have the capacity
to co-aggregate within the semi-fluid cell membrane (capping) and allow
the interaction of immunoreceptor thyrosin based activation motifs (ITAM)
and -inhibitory motifs (ITIM). These motifs promote phosphorylation and
dephosphorylation of signal transuding molecules, respectively. The cell
may be activated or inhibited depending on the outcome of receptor interactions
after capping. The relevance of these regulatory motifs to cell function
is especially well established for the antigen receptors of NK cells and
of T lymphocytes and for the function of Fc receptors. However, the phenomena
of "receptor crosstalk" has been observed in many other systems [77-85].
These developments indicate that numerous receptors are involved in cell
signaling, and that these receptors interact by multiple mechanisms that
may lead to activation, inhibition or even inactivation (apoptosis) [129].
Numerous receptors in immunology and several hormone receptors need to
be cross-linked by the ligand in order to deliver an activation signal
to a cell. This mechanism provides an important regulatory function in
that cross linking may take place only at an optimal concentration of the
ligand, whereas low or high concentrations would not be able to signal
the cells. When more than one receptor isotype is available, the homo-and
hetero-diamers formed by the specific ligand may have different regulatory
functions. In addition, cross-linking may be one of the important mechanisms
that promotes capping of the receptors prior to activation [77, 86, 87].
The immune system consists of mobile cells that are able to home readily
to specific target tissues and also to sites of infection, injury, regeneration
and healing. Stromal lymphoid cells play physiological roles and are very
important for host defense, regeneration and repair. Adhesion molecules
mediate immunocyte homing and lymphocyte recirculation. Blood vessels also
provide important barrier function in some tissues and organs that are
known as immunologically privileged sites. The blood-brain barrier is very
important from the point of view of neuroimmune interaction and is being
extensively studied at the present time [71, 86, 88-92].
Page
9
2.2.
Innervation
The central nervous system has the capacity to deliver neurotransmitters
and neuropeptides to all tissues and cells in the body. For a long time
the immune system was considered as an exception to this rule. However,
it is now clear that the thymus and the spleen and other lymphoid organs
are innervated. Interestingly, the spleen contains only sympathetic efferent
nerve fibers [93, 94]. Tissue mast cells are also innervated and the formation
of synapses with nerve fibers and lymphocytes can be readily demonstrated
in tissue culture. Neurogenic inflammation is the direct result of the
discharge of inflammatory mediators from mast cells after stimulation by
mediators (primarily substance P) released from sensory nerve terminals.
Neural mediators, such as growth factors, neurotransmitters, and neuropeptides,
(e. g. substance-P, somatostatin) play major roles in the regulation of
immune/ inflammatory responses. Nerve fibers are capable of rapid and specific
local delivery of mediators that are suitable of mounting an instantaneous
reaction by initiating inflammation. In other situations nerves may exert
an anti-inflammatory effect. The local modulation of immune reactions is
equally possible by neurotransmitters and neuropeptides [93-95].
During the acute phase response there is a massive release of catecholamines
into the circulation, which is known as "sympathetic outflow". Catecholamines
are important regulators in the acute phase response, which is an emergency
defense reaction. Sensory nerves provide feedback signals towards the CNS
from sites of injury, inflammation, and infection. The vagus nerve carries
feedback signals to the CNS from visceral organs [93-95].
2.3.
Humoral communication
Historically the humoral mediators of cell-communication have been classified
as hormones that act at distant targets, neurotransmitters and neuropeptides,
and locally produced hormone-like mediators, now called cytokines. One
may also include here immunoglobulins, which originate from B-lymphocytes
within the immune system. Immunoglobulins have evolved from adhesion molecules.
In addition, virtually every cell membrane bound molecule is present in
the serum, which includes MHC molecules and receptor-like-binding proteins.
By now it is clear that "classical" hormones, neurotransmitters and neuropeptides
are widely synthesized at various ectopic sites, including the immune system.
Moreover, cytokines, which have been originally discovered within the immune
system are now known to be synthesized in other tissues and organs, including
the neuroendocrine system. Therefore, the historical definition of hormones,
neurotransmitters and neuropeptides no longer applies. Rather, systemic
and locally produced mediators complement each other, so that optimal function
is assured both under physiological and pathophysiological conditions.
In addition to the blood stream, lymphatic drainage of tissues, including
the CNS, is important for humoral communication. The immune system receives
signals from all tissues via the lymphatic system [86, 92, 97, 98].
Page
10
3.
NEUROIMMUNE REGULATORY PATHWAYS
3.1.
The TRH-PRL, GH, IGF-I, TSH-thyroid axis
Thyrotropin releasing hormone (TRH) stimulates prolactin (PRL), thyroid
stimulating hormone (TSH) and under some pathophysiological conditions,
growth hormone (GH) release [99, 100]. Moreover, GH, PRL and TSH producing
pituitary cells share the nuclear regulatory factor, Pit-1 [101]. This
suggests that these hormones represent an interdependent regulatory unit.Indeed
in rats immunized with sheep red blood cells the increase of TRHmRNA was
found in the hypothalamus at 4-24 hours after immunization. Pituitary TRH
receptor mRNA and plasma PRL levels were also increased at the same time,
while TSH and GH did not change. The hypothalamus-pituitary-adrenal (HPA)
axis was activated 5-7 days after immunization. Antisense oligonucleotides
complementary to TRHmRNA, given i. c. v. inhibited PRL secretion and decresed
the titer of antibodies produced [102].
3.1.1.
Thyrotropin releasing hormone (TRH)
TRH affects directly lymphocyte proliferation and the development of T
lymphocytes in thegastrointestinal tract [103, 104]. In man, serum interleukin-2
(IL-2) levels rose significantly during the standard TRH test [105]. The
treatment of patients in critical illness repeatedly with TRH increased
serum TSH, PRL, GH, T4 and T3 levels, and may correct the euthyroid sick
syndrome [100].
3.1.2.
Growth and Lactogenic Hormones (GLH)
Growth hormone, PRL and placental lactogen (PL) are referred to collectively
as GLH. All three hormones show molecular heterogeneity and the variant
forms of GH and PRL differ in their biological activity. GLH hormones are
produced by a variety of cells in the body, including lymphocytes [106-116].
Our recent observations indicate that PRL production in lymphoid tissues
is pituitary dependent (Figure 2).
GLH and cytokines (e. g. G-CSF, GM-CSF, EPO, IL-2, -3, -4, -5, -6, -7,
-9, -11, -13) share receptor structure [117-120]. Receptors for PRL and
GH show heterogeneity and require cross-linking for signal delivery. At
high hormone concentrations, cross-linking will not take place, but rather
each receptor molecule will be bound to a separate hormone molecule, which
leads to the self-inhibition of signal delivery. Homo-and heterodiamerization
may take place after receptor-ligand interaction and some of the heterodiamers
lead to inhibition, rather than stimulation. More than one signaling pathways
play a role in GH and PRL action [86,117,119-123]. Both GH and PRL induce
the production of insulin-like growth factor-I (IGF-I) in cells of the
immune system. IGF-I receptors belong to the transmembrane thyrosine kinase
receptor family and are ubiquitously displayed on immunocytes [124].
The fetal pituitary gland does not play a role in the development of the
immune system. There is evidence to suggest that maternal and placental
lactogenic hormones fulfill this role [125-128]. After parturition, the
function of the bone marrow, the thymus and the maintenance of immunocompetence
all become pituitary dependent. The bone marrow deficiency of hypophysectomized
rats can be normalized by treatment with purified PRL, GH or PL [129-131].
IGF-I plays a role in the mediation of GH action on bone marrow [132, 133].
Colony stimulating factor-1 (GM-CSF) and interleukin-3 are capable of stimulating
IGF-I production in bone marrow cells and thus might function similarly
to GLH in this organ [134].
GH, PRL, PL and IGF-I all stimulate thymus growth [115, 126, 134-138].
This stimulatory effect is directly related to the maintenance of immunocompetence
[135].
GH, PRL and PL all promote the antibody response [128, 140]. Human pituitary
dwarf individuals have normal immune function, which can be explained by
the presence of normal serum PRL levels [139]. The dopaminergic drug, bromocriptine,
suppressed humoral immunity which could be reversed by treatment with either
GH or PRL. ACTH induced immunosuppression was also reversed by these hormones
[141]. PRL enhanced the antibody response in mice in a biphasic manner
as did syngeneic pituitary grafts [140, 141]. Cell mediated immune reactions,
including contact sensitivity reactions, graft rejection, graft versus
host reaction, and killer cell activity were stimulated by GLH [112, 128].
The tumoricidal activity of macrophages was also increased by PRL as was
the cytotoxic activity of natural killer (NK) cells. High concentrations
of PRL inhibited NK and lymphokine activated killer (LAK) cell activation
[142]. Recombinant GH corrected the decreased NK activity in GH deficient
children [143]. GH and PRL stimulated the activities of monocyte/ macrophages,
and polymor-phonuclear leukocytes [144-147].
Page
11
 |
| Figure
2. Pituitary dependence of prolactin production in lymphoid tissue. Female
or male Fischer rats (150-170 g) were used as normal controls, or were
hypohysectomized (HYPOX). Some rats were treated with a rabbit antiserum
against rat prolactin ("PRL, 50 µl/ day s. c."), which was initiated
on day 14 after hypophysectomy, and maintained until day 21, when extracts
of organs were prepared. For the release of tissue PRL 30 mg/ ml of wet
tissue was placed in serum-free RPMI 1640 culture medium and was frozen
(-20o C) and thawed (37o C waterbath) three times.
The tubes were then centrifuged, and the supernatants were tested for PRL
immuno-and bioactivity. Radioimmunoassy (RIA) [359] and the Nb-2 lymphoma
bioassay (BIO) [360] were used. This figure indicates that significant
quantities of immuno-and bio-active PRL was present in the thymus and spleen
of normal rats, which far exceeded serum levels. The thymus and spleen
of HYPOX rats contained only trace amounts of PRL. |
GH enhanced the production of IL-2 and IL-6 and had variable effects on
IL-1 and tumor necrosis factor-alpha;(TNF-alpha; ) production. PRL promoted
IFN-gamma; and inhibited IL-1 production [112, 148, 149]. The age-related
decline of immunocompetence may be due, at least in part, to the decline
of GH/ IGF-I production [141, 150, 151].
It is clear from this brief overview that GLH show redundancy as immunostimulatory
hormones. Current evidence suggests that GLH will support any function
performed by the immune system, including suppressor and killer cell
activities, which is compatible with the notion of competence hormones
[97].
Page
12
It has been suggested on the basis of experiments performed in knockout
mice, that PRL, GH and IGF-I are not obligate immunoregulators, but rather,
affect immune reactions as anabolic and stress modulating hormones [152,
153]. In actual fact the data obtained in knockout mice confirm our original
observations that GLH show overlap in the maintenance of the immune system.
By no means do these knockout experiments indicate the irrelevance of GH
and/ or PRL to immune function. In order to prove or disprove the relevance
of GLH to immunity, the entire system should be disabled. However, we predict
on the basis of our observations that such mutations would have lethal
consequences [154].
Much remains to be clarified with regards to the role of the various isoforms
of PRL and GH, and of their receptors, in immune function. Because the
receptor structure and the Jak-Stat transcription pathway of PRL and GH
are shared with interleukins and hemopoietic growth factors [87, 117],
some regard PRL and GH as members of the hemopoietic cytokine family. However,
functional overlap with cytokines could simply indicate the capacity of
systemic GLH to maintain the hemopoietic and immune systems at times when
cytokines are in short supply.
3.1.3.
TSH and thyroid hormones
TSH modulates immune function by the stimulation of thyroid hormones and
also by acting on lymphoid cells. TSH receptors are expressed on dendritic
cells and on CD45Rb high lymph node T cells. Recombinant TSH
significantly enhanced the phagocytic activity of dendritic cells from
adult mice and selectively augmented the IL-1beta; and IL-12 cytokine responses
following phagocytic activation. TSH also stimulated immunoglobulin secretion
and IL-2 production. Human lymphocytes treated with TRH released TSH [97,
155, 156].
Thyroid hormone receptors (TR) are nuclear transcription factors and belong
to the steroid-thyroid hormone receptor family. TR is encoded by two genes,
TR-alpha and TR-beta . Multiple isoforms of TR proteins are generated by
alternative splicing [157]. Lymphocytes convert thyroxin (T4) to bioactive
triiodothironine (T3). The effect of thyroid hormones on immune responses
is variable. Enhancement, suppression, or no effect was reported repeatedly.
While hypothyroidism is usually, but not always, associated with immunodeficiency,
treatment of normal animals with T3 yielded mostly negative results. In
TR knockout mice (TR-alpha-/- ) thymopoiesis
was suppressed. B cell maturation is depressed in mice that cannot respond
to thyroid hormones [97, 157, 158].
3.2.
The CRF-ACTH, alpha-MSH,beta-END, -glucocorticoid axis
The hypothalamus-pituitary-adrenal axis (HPA) and the proopiomelanocortin
(POMC) derived peptides (ACTH, alpha-MSH, beta-END) act antagonistically
to GLH and suppress adaptive immune/inflammatory responses by acting on
the nervous, endocrine and immune systems [97, 159].
3.2.1.
Corticotropin releasing factor (CRF)
During acute phase immune responses, cytokines stimulate CRF, which in
turn induces ACTH release. CRF integrates the stress response in the CNS
and exerts a central immunosuppressive effect by the stimulation of sympathetic
outflow. CRF is also produced within the immune system and has a direct
regulatory effect on lymphocytes, which is mostly, but not always, immunosuppressive
[49, 163, 164].
Page
13
3.2.2.
Adrenocorticotropic hormone (ACTH)
ACTH is immunosuppressive via the stimulation of glucocorticoid secretion
by the adrenal gland. ACTH is produced by lymphocytes and it has a direct
regulatory effect on lymphocyte proliferation, immunoglobulin production,
and phagocytosis. ACTH exerts an anti-pyretic effect in the CNS [97, 162,
165, 166].
3.2.3.
Beta-endorphin (beta-END)
Beta-END is produced and secreted by the pituitary gland and also within
the brain and immune system. Beta-END and opioids in general are immunosuppressive
when acting on the µ and kappa-opioid receptors. Opioids are also
capable of immunoregulation by acting on the CNS [164-167].
3.2.4.
Alpha-melanocyte stimulating hormone (alpha-MSH)
Alpha-MSH is a very effective antagonist of IL-1, -6, TNF, and IFN-gamma
. It inhibits fever and inflammation by acting on the CNS and also exerts
an antiinflammatory effect on peripheral targets. Alpha-MSH promoted tolerance
induction to contact sensitizing agents which was mediated by IL-10 [163,
168-170].
3.2.5.
Glucocorticoids (GC)
Glucocorticoid receptors are nuclear transcription factors and are present
in all cells in the body. Glucocorticoids suppress the adaptive immune
response, although evidence is increasing that basal physiological levels
are actually required for the normal function of lymphocytes. Elevated
pathophysiological levels (e.g. during systemic immune/inflammatory reactions,
trauma, or other stressful conditions) alter lymphocyte distribution in
the body and suppress humoral and cell mediated immunity. Mononuclear and
polymorphonuclear phagocyte function and cytokine production are suppressed
by elevated glucocorticoid levels. On the other hand, glucocorticoids increased
the expression of HLA antigens, and receptors for IFN-gamma , IL-1, IL-6,
Fc . Memory cells and the cells maintaining graft-versus-host reactions
are resistant to glucocorticoids. The thymic epithelium is capable of synthesizing
GC [97, 159, 171-176].
3.3.
Gonadotropins and sex hormones
In 5 normoprolactinemic women intravenous bolus injectin of luteinizing
hormone releasing hormone (LHRH) and TRH increased plasma IFN-gamma levels,
with the maximum response at 45 min after injection. Peak levels of PRL
appeared at 15 min; TSH: 30 min; FSH: 30 min; LH: 30 min. Moreover, LHRH
and TRH, separately and together, significantly enhanced in vitro IFN production
by staphylococcal enterortoxin-A (SEA) and concanavalin (ConA) -activated
peripheral blood mononuclear cells (PBMC) [177]. Luteinizing hormone (LH)
has a direct stimulatory effect on the immune system. Follicle stimulating
hormone (FSH) affected lymphocyte proliferation and IL-6 production [178-180].
Sex hormones play a major role in the regulation of mucosal immune responses
[181].
3.3.1.
Estradiol (E2)
E2
has a suppressive effect on bone marrow function, on the thymus, on T cell
function, NK cytotoxicity, neutrophil and mast cell degranulation. Phagocytosis,
antibody formation and certain forms of autoimmune disease are stimulated
by E2. The cytotoxic activity of CD4 + cells is dependent on estrogen [97,
182-185].
Page
14
3.3.2.
Androgens
Testosterone exerts a suppressive or moderating effect on the immune system,
it antagonizes the enhancing effect of estrogens on various autoimmune
diseases and stimulates bone marrow function. Aromatase inhibitors block
the effect of testosterone on the thymus [97,186, 187].
Dehydrotestosterone (DHT) has a stimulatory effect on T lymphocytes and
immunoglobulin formation. DHT is generated within the immune system from
androstenediol or testosterone by macrophages [188, 189].
Dehydroepiandrosterone (DHEA) is a weak androgen produced in the adrenal
glands. DHT and its metabolites have emerged as major regulators of immune
reactions capable of both immunostimulation and immunosuppression [190].
DHEA stimulates type 1 helper T cells (Th-1) for proliferation and IL-2
secretion and promotes cell mediated immunity. It antagonizes immunosuppression
by glucocorticoids. Age related immunodeficiency was reversed by DHEA in
mice and host resistance was increased against viral, bacterial and parasitic
infections. Vaccination and mucosal immunity was potentiated by DHEA. In
mice DHEA administration restored the depressed splenocyte proliferation
as well as IL-2, IL-3, and IFN-gamma production following trauma and hemorrhage.
In vitro the stimulatory effect of DHEA on splenocyte proliferation was
unaltered by the testosterone receptor antagonist flutamide, while the
estrogen antagonist tamoxifen completely abrogated its effect [191]. Serum
DHEA levels are decreased with aging, during chronic illness, suppressed
by dexamethasone treatment, and restored by ACTH treatment [192-195].
3.3.3.
Progesterone (PS)
Progesterone is a major immunosuppressive hormone and plays a key role
in the harmonization of immune function with reproduction. During pregnancy,
activated lymphocytes synthesize a progesterone induced blocking factor
(PIBF), which inhibits NK activity and exerts an anti-abortive effect.
Decidual CD56+ NK cells express PIBF. PS decreases host resistance to viral
and fungal infections and inhibits the function of phagocytes [97, 196-202].
3.4.
1-25-Hydroxy vitamin D3 (VD3)
The liver produces 25-hydroxy vitamin D3, which is further processed in
the kidney by 1-hydroxylase. This enzyme is also present in monocyte/ macrophages,
keratinocytes, bone marrow cells, placenta and in pneumocytes. The receptor
for VD3 is of 50 kDa protein and belongs to the superfamily of steroid/
thyroid hormone receptors [203, 204].
VD3 promotes the differentiation of macrophages, lymphocytes and of other
cell types. Monocyte/ macrophage phagocytosis and cytotoxicity is promoted
by VD3, whereas antigen presentation and cytokine production by T lymphocytes
and cell mediated immune reactions are inhibited. NK cell mediated cytotoxicity
is stimulated, B lymphocytes proliferation and immunoglobulin secretion
are inhibited by VD3 treatment. Experimental autoimmune reactions are prevented
by VD3 treatment. In man the treatment of psoriasis with VD3 analogues
has a 100% success rate [203-210].
3.5.
Melatonin
Melatonin (MEL) is secreted by the pineal gland. It regulates seasonal
breading in animals and is involved in the regulation of circadian rhythms
in vertebrates. Helper T cells express G-protein coupled MEL membrane receptors
and, perhaps, MEL nuclear receptors as well.
Page
15
MEL stimulates the release of Th-1 cytokines, such as IFN-gamma , and IL-2,
and of novel opioid cytokines which crossreact both with IL-4 and dynorphin
B. MEL was found to enhance the production of IL-1, -6 and -12 in human
monocytes. In general MEL exerts an immunostimulatory effect. Hematopoiesis
is also influenced, possibly by MEL-induced-opioids acting on kappa-opioid
receptors that are present on stromal bone marrow macrophages. IFN -gamma
and colony stimulating factors appear to influence the production of MEL
in the pineal gland. One intriguing feature of immunomodulation by MEL
is that it is effective only if given at the right time within the circadian
rhythm of the animal [213-218]. Much remains to be clarified about MEL
as an immunoregulatory factor.
3.6.
Nerve growth factor and neurotrophins
Nerve growth factor (NGF) was first detected in murine submandibular glands
as a growth factor for sensory and sympathetic ganglia [219]. NGF belongs
to the family of neurotrophins, that include brain derived neuroptrophin
(BDNT) and neurotrophin-3 (NT-3). There are low affinity neurotrophic receptors
(P25) and high affinity receptors, which are thyrosine kinases (e. g. gp140trkA
for NGF; gp145trkB primarily for BNDF; gp145trkC for NT-3). Human macrophages
express trkA and NGF is an autocine growth factor for these cells. The
thymus, lymph nodes, express trkA and the spleen trkB, localized primarily
to the stroma of these organs. There is some expression also
in splenocytes and thymocytes. B lymphocytes and antigen presenting cells
(follicular dendritic cells) also express receptors for NGF. NGF stimulates
the growth and function of mast cells, B and T lymphocytes, stimulates
IgM and IgG production, which is inhibited by IL-4. NGF inhibits the induction
of IgE by IL-4 [220-233].
T and B lymphocytes, macrophages and mast cells synthesize biologically
active NGF. NGF promoted the development of hemopoietic colonies and stimulated
the chemotactic and phagocytic activity of polymorphonuclear leukocytes,
which suggest a proinfl ammatory role for NGF. However, in vivo
the suppression of inflammation has also been observed by NGF in several
experimental models. Recent observations indicate that immune derived NGF
provides protection for the nerveous system and to other host tissues during
inflammatory reactions. This phenomenon implies the existence of beneficial
'autoimmune' reactions [224-245].
3.7.
Leptin
Leptin (LEP) is produced primarily by fat cells (adipocytes). Structurally
LEP belongs to the GLH/ CTK family and signals by a class I cytokine receptor
(Ob-R). Two receptor isoforms are known: Ob-Ra and Ob-Rb. Leptin regulates
energy metabolism, reproductive function, lymphoid development and function.
Under normal physiological conditions the secretion of LEP is regulated
by insulin, cortisol and sex steroids, mainly testosterone.
In
rats centrally administered LEP suppressed the mitogenic response of splenic
lymphocytes. This was mediated through CRF-sympathetic activation. Leptin
plays an important role in linking nutritional state and T cell function.
In starving mice, which show immunosuppression, treatment with LEP enhanced
TH1-mediated immune responses, in spite of the catabolic state of the animals.
Starving animals have reduced LEP levels and show an increased sensitivity
to endotoxin shock. Fasting mice respond to LPS with a blunted corticosterone
and exaggerated TNF production. This could be corrected by LEP treatment
[246-253].
During acute phase responses (e. g. sepsis) the serum level of LEP rises
rapidly. Cytokines, especially TNF-alpha , causes this elevation. LEP exerts
an inhibitory effect on glucocorticoid and IL-6 production. Blood levels
of LEP correlate positively with the survival of patients with septicemia.
LEP stimulates the production of IL-1 receptor antagonist (IL-1ra), which
protects against LPS toxicity in mice. In murine glial cells LEP stimulated
the production of IL-1beta . In animal experiments exogenous LEP upregulated
both phagocytosis and the production of proinflammatory cytokines. Leptin
is also involved in wound healing and angiogenesis [251, 254-260].
Page
16
3.8.
Neurotransmitters and neuropeptides
3.8.1.
Catecholamines and acetylcholine
Various cells in the immune system express beta-type adrenergic receptors.
Beta-adrenergic agents inhibit allergic and asthmatic reactions and in
general inhibit various immune phenomena that include lymphoid responses
to mitogens and to antigen, histamine release from leukocyctes and mast
cells and skin reactions to antigen and histamine. The effect on antibody
formation is variable. In vivo adrenalin elicits leukocytosis and
eosinophilia which is followed by eosinopenia. At least some of these effects
on leukocyte distribution are due to glucocorticoid release. Noradrenaline
inhibits the histamine release from leukocytes and the degranulation of
mast cells and it has a variable effect on antibody formation. In mice
treated with LPS the reduction of sympathetic outflow by reserpine dramatically
increased TNF production. Neuronal alpha 2-and macrophage beta-and alpha
2-receptors were involved. In healthy volunteers catecholamines down regulate
LPS-induced TNF-alpha , IL-6 and IL-1beta , and increased IL 10. In patients
with prolonged sepsis TNF-alpha and IL-6 were reduced and IL-1beta and
IL 10 were not modulated by catecholamines [261-269]. The role of the peripheral
and central catecholamine systems on immune regulation is the subject of
intense investigations at the present time. Acetylcholine affects immune
phenomena by nicotinic and muscerinic receptors. Cholinergic agents enhance
immune phenomena, including lymphocyte mitogenesis, cytotoxic reactions,
the release of histamine and other mediators from mast cells. These effects
are meditated by muscarine receptors. Acetylcholine stimulates the synthesis
of complement components by human monocytes through the nicotinic receptor.
Allergic patients show an increased sensitivity to cholinergic stimulation.
The involvement of cholinergic mechanisms in exercise-induced anaphylaxis
has been demonstrated [261, 270-273].
3.8.2.
Substance-P (SP)
Substance-P mediates pain sensation in type C sensory nerve fibers and
is a major mediator of neurogenic inflammation. Thymocytes, B and T lymphocytes,
macrophages, mast cells and astrocytes have SP receptors. SP is capable
of inducing degranulation of mucosal and intestinal type of mast cells,
can cause plasma extravasation and bronchoconstriction. Substance P has
a direct effect on lymphocytes, macrophages, eosinophils and neutrophils.
It promotes lymphocyte proliferation, lymphokine production, and it has
variable influence on immunoglobulin secretion. On eosinophils, SP increases
Fc-gamma and epsilon-receptors and decreases C3b receptors. SP stimulates
the respiratory burst, chemotactic and phagocytic responses in polymorphonuclear
leukocytes. Substance P stimulates the release of PGE2and
collagenase from rheumatoid synoviocytes and of PGE and thromboxane B2
from astrocytes. Platelet cytotoxicity against Schistosoma mansoni larvae
is activated by SP. SP induced IL-3 and GM-CSF production by bone marrow
cells. This was partially mediated by IL-1 and IL-6, which are also induced
by SP in the bone marrow. SP receptor expression is up-regulated by IL-4
and IFN-gamma in murine peritoneal macrophages. The SP receptor was necessary
for the normal granulomatous response to Schistosoma mansoni [274-285].
Page
17
3.8.3.
Calcitonin gene related peptide (CGRP)
CGRP receptors are functionally coupled to adenylate cyclase and are present
on mature lymphocytes, macrophages mast cells and bone marrow cells. CGRP
induces mast cell discharge, produces slow onset intense erythma in the
skin and vasodilation. In human mononuclear phagocytes CGRP interferes
with antigen presentation and with IFN- alpha induced
H2O2
production. Lymphocyte proliferation is also inhibited by CGRP. Nerve fibers
containing CGRP are associated with Langerhans cells in the human skin.
CGRP plays an important role in the regulation of the cutaneous immune
system. It inhibited antigen presentation by human Langerhans cells, and
the induction of contact hypersensitivity reactions to haptens in mice.
Topically applied CGRP increased the inflammatory response in the skin
to allergens and irritants and boosted the sensitization process. In murine
thymocytes CGRP inhibited the expression of NF-kappa B and promoted apoptosis.
T lymphocytes from rat thymus and mesenteric lymph nodes sythesized CGRP
[286-293].
3.8.4.
Somatostatin (SOM)
Receptors are present on T and B lymphocytes and mast cells for SOM. SOM
acts as an antagonist of substance P and it has beneficial effects in models
of autoimmune disease and of chronic inflammation. SOM inhibits IgE dependent
mediator release by human basophils and mast cells. It also inhibits lymphocyte
proliferation, endotoxin-induced leukocytosis, IgA secretion, IFN-alpha
production, and affects macrophages. It has a variable effect of antibody
dependent cytotoxicity [274, 275, 294-298].
3.8.5.
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating
peptide (PACAP)
Receptors are present in monocytes and lymphocytes and both peptides are
produced within the immune system. VIP regulates T cell homing to mucosal
lymphoid tissue, it inhibits lymphocyte proliferation and has a variable
effect on immunoglobulin secretion and on NK cell mediated cytotoxicity.
IgA secretion was induced by VIP by isotype switching [299-303]. VIP and
PACAP inhibit the nuclear translocation of NF-kappa-B in stimulated macrophages
by inhibiting Jak/ Stat phosphorylation and thus antagonize the effect
of IFN-gamma and downregulate the inflammatory response. The production
of cytokines, such as TGF-beta 1, IL-12, IL-4, -6, TNF-alpha and nitric
oxide (NO) are inhibited by both peptides [304-309]. IL-6 production was
enhanced by VIP/ PACAP in unstimulated macrophages [310]. VIP and PACAP
inhibited antigen induced apoptosis in CD4+ (but not CD8+) T lymphocytes
by downregulating Fas [311]. VIP and alpha -MSH contribute to the immunosuppressive
properties of aqueous humour in the eye [312, 313]. In man VIP inhibited
the development of contact dermatitis to nickel sulphate when injected
intracutaneously at the site of challenge [314].
3.9.
Cytokines
Cytokines have been originally discovered within the immune system as humoral
mediators between leukocytes (interleukins). By now it is clear that cytokines
are produced in all tissues and organs in the body. Under physiological
circumstances cytokines are local regulators of tissue/ organ function.
However, during acute phase reactions cytokines such as IL-1, TNF-alpha
and IL6 serve as systemic hormones and induce profound neuroendocrine and
metabolic alterations, which serves to boost the natural resistance of
the body towards diverse noxious agents. Some other cytokines with major
roles in the neuroimmunoregulatory system are interleukin-2, -4, -10, &
interferon- gamma (IFN-gamma ). Redundancy is present within the cytokine
system in that these mediators have overlapping functions. This is now
well substantiated with experiments
preformed
in various knockout mice [97, 315-318].
Page
18
3.10.
Chemokines (CEM)
These are chemotactic pro-inflammatory mediators, which are produced in
response to injury, irritants, polyclonal activators, antigens and cytokines.
As inflammatory mediators CEM play important roles in host defence as well
as in the pathogenesis of inflammatory diseases. Chemokines also serve
as mediators of cell-to-cell communication within the immune system and
promote humoral and cell-mediated immune reactions, regulate cell adhesion,
angiogenesis, leukocyte trafficking and homing and contribute to lymphopoiesis
and hematopoiesis. A vast number of CEM have been identified to date which
may be categorized, based on their structures, into four major groups:
CXC (alpha ), CC (beta ), C ( gamma) and CX3C
subfamilies. Chemokine receptors are seven-transmembrane G proteins.Chemokines
show unprecedented redundancy in receptor utilization and leukocytes express
multiple receptors [315, 318]. Chemokines play a fundamental role in cell-to-cell
communication throughout the body and enable every cell/ tissue to emit
signals towards the neuroimmune regulatory network.
3.11.
The neuroexocrine-mucosal system
The mucosal immune system consists of mesenteric lymph nodes, Peyer's patches,
the tonsils, mucosa associated lymphoid cells and lymphoid cells associated
with various glands (eg. salivary and lacrimal). It is now apparent that
the mucosal immune system does not only defend the body against invading
pathogens but also exerts major regulatory effects on systemic immune reactions.
The problem faced by the mucosal immune system is that mucous membranes
are bombarded by large amounts of antigens continuously, most of which
are irrelevant to host defense. It would be counter-productive to spend
a lot of immunological energy to respond to harmless antigens. On the other
hand pathogenic agents and potentially harmful toxic substances must be
dealt with. Immune defense is already mounted on the surface of mucous
membranes, which are outside of the body. Therefore, self-non-self discrimination,
which is being utilized so efficiently by the immune system inside the
body, does not apply to this situation [110, 319-323].
The initial response to antigens falling on mucosal surfaces is frequently
the induction of immunological tolerance. This may take place by clonal
elimination at high antigen dosage or by active suppression if the dosage
is low. Although the mechanisms that regulate tolerance induction has not
been fully elucidated, it appears that antigen presentation by specialized
cells that induce a distinct class of T cells capable of suppressing immune
responses locally and systemically takes place. These T cells have been
named as a type 3 T (TH3) cells and produce large amounts of transforming
growth factor- (TGF)-beta. TH3 cells exert a powerful systemic immunosuppressive
effect all over the body at sites of inflammation and on cells of lymphoid
tissue [324, 325].
Mucosal mast cells are distinct from those situated in other tissues and
play important roles in the physiology and pathophysiology of mucous membranes.
The submandibular gland in laboratory rodents has been identified as a
neuroendocrine and neuroexocrine organ secreting antimicrobial substances,
immunoglobulin, hormones and enzymes that play major roles in mucosal immune
reactions as well in the regulation of inflammation, regeneration and repair
within mucosal tissues and elsewhere in the body. The sympathetic superior
cervical ganglion-submandibular gland axis has been suggested as one of
the major immunoregulatory pathways [322].
Page
19
The submandibular gland produces, secrets and excretes significant amounts
of nerve growth factor, epidermal growth factor and TGF-beta , all of which
are powerful immunoregulators. Glandular kallikrein, an enzyme with a potent
immunosuppressive effect, is also produced. This enzyme was shown to suppress
immune reactions and inflammation when applied parenterally to animals
and to play a role in the induction of oral immunological tolerance when
given by mouth [321, 323, 326].
It has been demonstrated in the gut that must cells are innervated and
that these cells play an important role in intestinal absorption as well
as in pathological responses, such as the initiation of inflammation and
so on. Lymphocytes exposed to antigen/ infectious agents at a particular
mucosal site will multiply, differentiate and redistribute to other sites
of mucosal membranes through re-circulation, which provides generalized
protection. This is known as the "common mucosal immune system" [285, 327].
4.
BASIC CONCEPTS AND PRINCIPLES IN NEUROIMMUNOREGULATION
The rapid accumulation of experimental data in diverse systems that has
relevance to neuroimmunoregulation has led to contradictions, misconceptions
and confusion. These problems need to be addressed and clarified. Some
of the key issues are addressed below both from the theoretical and practical
points of view.
4.1.
The concept of competence
It has been known for over a century that GH is capable of promoting the
proportional growth of all tissues and organs in the body. Naturally, this
includes the immune organs, such as the spleen, thymus and lymph nodes.
Receptors for GLH are expressed on every tissue and organ in the body.
Current indications are that all cells require some members
of
this hormone family for normal growth and function. GLH in conjunction
with IGF-I exert a growth stimulatory and an anti-apoptotic effect on various
cells and thus assure maintenance in a functional state, i. e. the cells
are capable of responding to additional stimuli. On this basis GLH may
be defined as competence hormones. There is much evidence in the literature
indicating that the immune system is dependent on GLH for the maintenance
of immunocompetence. This is related to the general function of these
hormones
to maintain growth and development, and lymphocyte growth is a prerequisite
for adaptive immune reactions [97, 129, 135].
On the other hand, a vast amount of experimental evidence has accumulated,
indicating the role of tissue specific growth factors, cytokines and adhesion
molecules in cell-to-cell signalling and the regulation of growth, differentiation
and function of various cells in the body. It is apparent that proportional
growth, although ultimately controlled by the systemic level of GH, is
achieved through the coordinated interaction of systemic and local growth
regulatory signals, many of which are tissue/ organ and are also function-related.
Current evidence indicates that GH in conjunction with IGF-I maintain all
cells in a state of competence to respond to additional, function-related
stimuli and produce additional regulatory mediators. Prolactin, which may
be regarded as a modified growth hormone, is capable of providing competence
in most tissues and organs in the body with the exception of the skeleton,
where its growth promoting effect is very limited. Like GH, PRL also induces
IGF-I in its target cells. The IGF-I signal may be regarded as the ubiquitous
cytokine signal that is needed for the survival of competent cells. On
this basis one may hypothesise, that competence hormones maintain their
target cells in available and responsive state by a direct stimulatory
effect on the genome and by the induction of IGF-I secretion.
Page
20
Ultimately,
the proliferation and functional activation of cells is determined by adhesion
molecules, which are capable of delivering non-diffusible cell-to cell
or cell-to-matrix signals. Adherence signals are capable of regulating
cell function specifically on an individual basis. For example, an antigen-presenting
cell delivers regulatory signals to an antigen specific T lymphocyte [129].
Prolactin synthesis is detectable in numerous tissues, including lymphoid
tissue [97,154]. There is compelling evidence to suggest that tissue-derived
PRL fulfils autocrine/ paracrine regulatory functions. Within the immune
system, small lymphocytes are in a quiescent state and do not synthesize
significant amounts of mediators. They need to be activated in order to
do so. Based on current experimental evidence, one may propose that inactive
small lymphocytes are dependent for survival on pituitary GH/ PRL and IGF-I.
The dependence of cell survival in the thymus, spleen and bone marrow on
GH/ PRL supports this hypothesis. Moreover, pituitary PRL and GH maintain
vital bodily functions and thus must act as survival hormones for the entire
organism [128, 135, 328]. Animals with joint and total deficiency of GH/
PRL do not exist, and such deficiency has not been convincingly demonstrated
in man to date [154, 329]. The proposed interaction of neuroendocrine factors
with adhesion signals and paracrine circuits in the regulation of bodily
functions is summarized in Figure 3.
4.2.
Redundancy
Failure
of the neuroimmune regulatory system invariably leads to the death of the
organism. In order to avoid frequent failures, the system must have multiple
and overlapping regulatory pathways with a high degree of flexibility and
plasticity. This is achieved through isologous forms of regulatory molecules,
multiple forms of receptors, and by the existence of functionally overlapping
or totally interchangeable regulatory pathways. The CNS shows a high degree
of plasticity. Moreover, redundancy is present in the function of growth
and lactogenic hormones, of the IGF/ insulin system, of steroid hormones,
neuropeptides, cytokines, chemokines and of the various immunoglobin classes.
It is quite common in immunology that unsuspected redundancy is revealed
in the system by knocking out a particular gene. Similarly, the disabling
of prolactin or growth hormone, or even IGF-I, would not paralyze immune
function [85, 152]. These facts and clinical observations indicate clearly
that the functional integrity of the neuroimmune regulatory network is
maintained, even after very severe insults/deficiencies due to the existence
of redundant physiological and pathophysiological mechanisms.
4.3.
Homeostasis
Healthy
individuals and animals maintain their body temperature, blood pressure
heart rate
metabolism
and the concentration of various ingredients in the serum and in tissue
fluids within standard physiological ranges, which is characteristic of
the species. This was first recognized by Claude Bernard over a century
ago, who coined the term "milieu interieur" [330], now designated as homeostasis.
Under homeostatic conditions two basic forms of immune reactivity can be
observed, e. g., innate or natural immunity and adaptive immunity.
Page
21
4.3.1.
Natural immunity

Figure
3. The interaction of neuroendocrine and autocrine/ paracrine regulatory
pathways. This figure depicts some basic neuroendocrine and paracrine interactions
in immunoregulation with reference to other cells (Please see the text
for details). It is proposed that the maintenance of all cells in the body
in a functional state is dependent on competence hormones. Additional signals
are required for tissue and cell-specific regulation that include adhesion
molecules and cytokines. 1. Competence signal: This signal is delivered
to lymphocytes and to many other cells in the body by GH and/ or PRL, produced
in the pituitary gland. GH and PRL are also produced in many tissues ectopically,
including the immune system. Ectopic PRL/GH fulfill a local regulatory
function during immune reactions. It is suggested that this autocrine/paracrine
circuit makes rapid lymphocyte proliferation possible, which is a prerequisite
of immune reactions. 2. Stromal/ adherence signals: Antigen presentation
is best known as an activation signal for lymphocytes. It is an adherence
signal delivered by MHC molecules on antigen presenting cells. This is
accompanied by additional co-stimulatory adherence signals, which may eventually
lead to lymphocyte activation. Adherence signals also play a role in the
induction of immunological tolerance, in lymphocyte survival, and in the
induction of programmed cell death (PCD). It is proposed that adhesion
signals fulfill tissue-, site-and cell-specific regulation in the body,
i. e. the function/ fate of individual cells are determined at this level.
3. Cytokine signals: Lymphocyte activation, and cell activation
in general is completed by cytokine signals, which lead to cell proliferation,
differentiation, and functional activation. Cytokines may also perform
inhibitory function (e. g. TGF-beta , interferon-gamma ) or cause PCD (e.
g. tumor necrosis factors). a. Signal modulation: Some steroid hormones,
catecholamines and endorphins/ enkephalins are capable of modulating the
process of signal delivery from the cell membrane to the nucleus by regulating
Ca 2+ influx, cAMP and cGMP. b. Signal regulation: Thyroxin
(T4) and steroid hormones (SH) control lymphocyte signaling by the regulation
of nuclear transcription factors. Thyroxin, steroid hormones and vitamin
D3 play a regulatory role also in cell differentation and in the elimination
of unwanted cells via the induction of PCD. c. Local hormone activation:
Bioactive thyroid and steroid hormones are locally generated from inactive
precursors by immunocytes (e. g. T3, E2, androstenediol, androstenetriol,
and vitamin D3) while the primary function of others (corticosteroids,
estradiol, progesterone, aldosterone) is systemic immunoregulation. Quiescent
lymphocytes do not synthesize DNA and exert minimum metabolic activity.
Pituitary GH/ PRL, some adhesion signals and serum IGF-I play a key role
in the maintenance of these lymphocytes until functional activation occurs.
Neurotransmitters and neuropeptides are locally acting functional regulators,
basically acting as signal modulators and cytokines.
Page 22
The
natural immune system consists of some highly specialized cells such as
natural killer cells, T cells and CD5+ B lymphocytes, that produce natural
antibodies. The antigen receptors of these cells are germ line coded, which
are not subject to somatic mutation. These receptors have evolved to recognize
highly conserved homologous epitopes (homotopes) on microorganisms and
in self-components and react instantaneously to their respective homotopes
without the need of previous immunization. Natural antibodies are germ
line coded and are polyspecific. Some liver derived proteins, namely C-reactive
protein, endotoxin-binding protein, mannose binding protein, are also capable
of recognizing homotopes, and to activate immune reactions [320, 331, 332].
Non-immune factors contribute to innate resistance. In this context behavioural
factors, physico-chemical factors, barriers, mucus, enzymes, anti-microbial
substances, (HCL, bile acids, nitric oxide, oxygen radicals) heat shock
proteins, non-immune interferons, enzymes, properdin, prostaglandins, leukotrienes,
chemokines, blood clotting, species related resistance due to cell surface
receptors and other factors may be mentioned. Typically it is not the antigen
but cytokines and hormones that are fundamental to the regulation of natural
immunity. For instance, in the regulation of NK cell mediated cytotoxicity
interleukin-2, interferons,prolactin and growth hormone play important
roles [332].
4.3.2.
Adaptive immunity
The
adaptive immune response is initiated by antigen presenting cells that
activate antigen specific thymus derived (T) lymphocytes bearing alpha/beta-
type antigens receptors. Bone marrow derived (B) lymphocytes recognize
antigen by surface immunoglobulin receptors and produce antibodies. The
antigen receptors of B and T lymphocytes undergo somatic mutation, followed
by selection of those cells that do not possess self-reactivity but will
react to altered-self MHC antigens. Because of the elaborate selection
process adaptive immune responses show exquisite specificity. Processed
antigenic fragments (epitopes) are presented to T-lymphocytes by antigen
presenting cells in association with surface MHC molecules. Antigens may
come from the external environment or from within the body (e.g. virus
infected cells, cancer cells, autoantigens etc). Externally derived antigens
are presented by MHC class II antigens to CD4+ T cells, whereas endogenous
antigens produced by virus infected and by cancer cells are presented by
MHC class I antigens to CD8+ T lymphocytes [86].
Although the adaptive immune response is initiated by specific epitopes
of the antigen, it is very well substantiated that additional "costimulatory
signals" are also required for full activation of lymphocytes, for the
initiation of cell proliferation, differentiation and for functional performance.
In some situations the antigen signal is followed by inhibitory rather
than stimulatory adherence signals, which lead to the induction of unresponsiveness,
known as immunological tolerance, or anergy [86, 129].
Lymphocyte activation follows the rules of mitosis in general and involves
cascades of enzymatic reactions, which is accompanied by Ca 2+
influx and ultimately leads to the phosphorylation of nuclear regulatory
proteins. Hormones are capable of modulating the process of signal delivery
from the membrane receptor to the nucleus by regulating Ca
2+ influx, or by the modulation of cyclic nucleotide
levels, or some enzymes, etc. (e. g. catecholamines, some steroid hormones,beta
-END and other opioid peptides) [97, 129]. This is designated as signal
modulation (Figure 3). The origin of signal modulatory hormones may
be exogenous or endogenous to the immune system.
Thyroid and steroid hormones, and vitamins A and D, control nuclear transcription
factors as their receptors, and are capable of regulating lymphocyte signals
at the nuclear level. Because of the ability of these hormones to cross
the cell membrane and home to their cytoplasmic/nuclear receptor molecules,
they are capable of bypassing the cytoplasmic signal transduction pathway
and amplify, suppress or even cancel completely, certain lymphocyte signals
in the nucleus. For instance, glucocorticoids are very efficient in the
inhibition of ongoing lymphocyte reactions. Hormones belonging to this
category are designated as signal regulators (Figure 3). Some of these
nuclear regulatory hormones (e.g. T3, E2, androstenediol and androstenetriol,
vitamin D3) are synthesized within the immune systemand function in an
autocrine/paracrine fashion. These locally produced hormones are required
for normal immune function (e.g. T3, GC, DHEA and its metabolites). Others
act as powerful immunoregulators (e.g. E2, elevated GC levels, PS) and
have the capacity to amplify, suppress/ terminate ongoing immune reactions.
Moreover, glucocorticoids are able to kill thymocytes and lymphocytes by
inducing PCD, whereas other steroid hormones sensitize target cells for
killer cell induced PCD [183].
Page
23
The final category of signals that complete the mitogenic stimulus to lymphocytes
are delivered by cytokines. If the antigenic signal is not complemented
with the proper cytokine response, it is followed by activation-induced
programmed cell death. The major cytokines involved in the induction of
T cell mediated immunity (delayed hypersensitivity reactions, cytotoxic
T lymphocytes) are IL-2 and IFN-gamma . These are produced in large quantities
by type 1-helper T lymphocytes (TH1). In contrast, humoral immunity is
stimulated by IL-4, -5, -6 and -10, which are secreted by TH2 cells in
large quantities. Although this classification of T cells is very convenient,
it is recognized that intermediate cells are not uncommon, which provides
plasticity and redundancy in the system. The primary antibody response
always starts with IgM, which is followed by switching to other immunoglobin
classes (e. g. IgG, IgA and IgE) while maintaining epitope specificity.
This way a whole range of antibodies may be produced against the same epitope
that have the capacity of activating diverse immune effector reactions,
such as phagocytosis, complement fixation, cytotoxicity etc., against the
same target. The primary immune response needs 5-10 days to provide efficient
protection for the host, whereas secondary responses are much faster and
can protect the host within less than 5 days. During the immunization period
the organism must rely on natural immune mechanisms for protection [85,
332].
In health the immune system provides protection against infectious disease
and diverse insults, while homeostasis is maintained. Typically subclinical
infections and insults are contained, the pathogenic agents are eliminated
and the injury repaired locally. This, however, does not mean that the
neuroendocrine and immune systems do not interact under these conditions.
There is ample evidence to indicate that the "homeostatic milieu" with
well defined levels of hormones, cytokines, neurotransmitters and neuropeptides
is fundamental to this immune homeostasis.
Many physiological reactions can be considered as adaptive responses, which
are required for coping with altered functional demands. Thus for instance,
exercise commands higher blood pressure, heart rate, altered endocrine
function, metabolism, and leads to immune alterations. The hypertrophy
and atrophy of organs according to functional demands is also commonly
observed. Adaptive enzyme synthesis is another example of adaptive responses
other than the immune response. Clearly, responses analogous to immunization,
tolerance induction and apoptosis are all observable in various tissues
and organs of the organism.
4.4.
The acute phase response (APR)
The
highly coordinated and multi-faceted defense reaction described by Hans
Selye as the general adaptation syndrome [9], is now known as the APR [334].
Fever is the unmistakable hallmark of APR, which is capable of increasing
host resistant to diverse insults within hours. While liver derived proteins
and natural antibodies increase rapidly during APR, the thymus undergoes
a profound involution. The adaptive immune response is suppressed. At the
same time natural immune defense mechanisms are amplified several hundred
to a thousand times within 24– 48 hours. Immune derived cytokines, primarily
IL1, IL6 and TNF-alpha initiate the reaction by activating leukocytes and
acting on the central nervous system and on numerous other organs and tissues
in the body. This triggers the HPA axis for increased activity. The secretion
CRF, ACTH, alpha-MSH, beta-END and glucocorticoids is rapidly increased.
Hormones of this axis suppress the adaptive immune response and regulate
fever and inflammation by acting on the nervous-, endocrine-and immune
systems [334-338].
Page
24
Circulating GH and PRL levels quickly rise at the beginning of febrile
illness and soon return to normal-to-subnormal levels. The IGF-I response
to GH stimulation is impaired and the conversion of thyroxine (T4) to tri-iodothyronine
(T3) in the tissues is also inhibited. Sex hormone levels are suppressed
and testosterone levels may stay subnormal for lengthy periods. The levels
of insulin and glucogen are consistently elevated, although insulin resistance
is present [320, 331, 332, 334-338].
Interleukin 6 levels are grossly elevated in APR. This is a pleiotropic
cytokine, which stimulates the production of acute phase proteins (APP)
in the liver. Glucocorticoids and catecholamines support the production
of APP, which rise rapidly in the serum to maximum levels (up to 1,000x)
within 1-2 days. Natural antibody levels also show an abrupt increase.
By this the serum concentration of polyspecific defense molecules, such
as natural antibodies, LPS binding protein, C-reactive protein, mannose-binding
protein is increased enormously. Complement production is also elevated,
potentiating further the efficiency of polyspecific defense molecules.
A number of APP function as enzyme inhibitors and inhibitors of inflammation,which
are likely to provide damage control during febrile illness [334-339].
All these changes are consistent with the rapid enhancement of polyspecific
host resistance to infection and to various other insults as originally
observed by Selye (Figure 1).
Febrile illness is an emergency defense reaction, which takes over the
task of host defense in situations when other defense mechanisms, including
adaptive immunity, have failed. During APR the adaptive immune response,
which is dependent on T cells, is suppressed and the immune system is placed
under the command of natural antibodies and liver derived recognition molecules.
These molecules are capable of recognizing homotopes on pathogens and on
altered self components and activate various immune mechanisms after combining
with their specific target determinants. In this situation interleukin
6 is likely to function as an emergency competence hormone and insulin
may be the principle growth factor fuelling elevated leukocyte production
and activity. Elevated serum levels of leptin ensure the energy requirements
of APR. Inhibitory cytokines, such IL1 receptor antagonist, TNF synthesis
inhibitor, IL10 and leukemia inhibitory factor are also elevated and participate
in the regulation of inflammatory processes. During APR INF excess serves
as an antagonist of these cytokines [247, 255, 256, 259, 334-339].
The immunoconversion during APR from the adaptive mode of reactivity to
the amplification of natural immune mechanisms provides instantaneous and
rapidly increasing defense at the expense of muscles and other tissues
and organs, which undergo catabolism. Therefore, the natural immune system
provides the first line of host defense during health and it also serves
as the last resort of host defense in crisis situations. The acute phase
response is a highly coordinated pathophysiological reaction where cyctokines,
inflammation and the metabolic activity of various organs and tissues are
tightly regulated, all in the interest of host defense [332]. For this
reason McEwen has adapted the term "allostasis" in contrast with homeostasis
[340]. Indeed evidence is rapidly increasing that the "allostatic milieu"
is a prerequisite for the suppression of the adaptive immune response and
the amplification of innate immunity.
Page
25
Practical
observations indicate that APR is a very effective defense reaction indeed,
as in the overwhelming majority of febrile illness recovery is the rule,
which is followed by the development of specific immunity.
5.
SUMMARY AND CONCLUSIONS
The
stroma of various tissues and organs fulfills an important regulatory function
towards the paranchymal cells that perform the specific tasks characteristic
of the organ/ tissue. Lymphoid cells (monocytes, macrophages, T and B lymphocytes,
specialized antigen presenting cells, mast cells) are invariably present
in the stroma and contibute to regulation. There is evidence for this in
the nervous system, in the gastrointestinal tract, in the pituitary gland,
in the adrenals and gonads, breast tissue and in other reproductive organs
and in the skin. Cell-to-cell communication takes place within tissues
and organs via adhesion molecules, which may be tissue-site-and cell-specific
or shared with other organs and tissues. Adherence signals may promote
or inhibit function, depending on the local requirements. Matrix components
also deliver local regulatory signals.
PRL, GH and IGF-I maintain the cells and tissues of the body in a functional
competent state. Most tissues have the capacity to synthesize PRL, GH and
IGF-I. This local production allows for tissues/ organs/ systems to amplify
locally specific functions and to increase the adaptability of the organism
(e. g. the adaptive immune response). Tissue specific growth factors may
fulfil the role of competence hormones (possible examples are: IL-2, IL-3,
IL-6, GM-CSF, epidermal growth factor, fibroblast growth factor). This
remains to be established. Therefore, it is suggested that tissues/ organs/
systems function as partially independent units, capable of generating
all three categories of regulatory signals upon functional demands. This
provides flexibility and plasticity for adaptation to the requirements
that need to be fulfilled.
Various cells of the immune system home to organs and tissues specifically.
This is governed by tissue specific adhesion molecules and by humoral signals
such as chemokines, and cytokines. Monocyte/macrophage type cells and mast
cells take up residence in the tissues and there is evidence for tissue
specific differentiation. Examples of differentiation are the glia cells
in the brain, mucosal versus the connective tissue type mast cells, Langerhans
cells in the skin, Kupffer cells in the liver, and dendritic cells throughout
the body. Endothelial cells mediate the communication between leukocytes
and specific tissues via cytokines and adhesion molecules. The endothelium
may also serve as a barrier between leukocytes and the tissue (e.g. blood
brain barrier), but are also involved in the increase of vascular permeability
during inflammatory reactions.
The CNS has dominant regulatory powers in the body that includes the regulation
of immune phenomena. The regulation of the inflammatory response by nerve
impulses, the phenomenon of conditioning immune responses, the intricate
and sophisticated neuroimmune mechanisms that are built into the process
of reproduction in higher animals, especially mammals, the fact that emotions
and stress affect immune reactivity are all examples pointing to CNS control.
Immune phenomena show circadian and seasonal variation and this also indicates
the existence of neuroendocrine regulatory influences. The sleep-wake cycle
is fundamental to the maintenance of health and normal immune function
[98, 285, 341-345]. Therefore the neuroimmune regulatory network is fundamental
to the maintainence of health.
Our initial experiments revealed the important role of hormones secreted
or regulated by the pituitary gland in immunodeficiency, in hematopoiesis,
in the cytokine response to infectious agents, in autoimmune diseases,
in host resistance to cancer and in the overall survival of the organism
[38-42, 128, 135, 154, 183, 329, 346-353]. Currently there is much evidence,indicating
that abnormalities of the neuroimmunoregulatory network are associated
with diseases of the nervous -, endocrine -, and immue systems and indeed,
of other tissues and organs. It is beyond the scope of this overview to
discuss this subject in detail. Instead, some recent publications are cited
for the interested reader in addition to the ones presented in this volume
[354-358].
Page
26
One may conclude on the basis of available evidence that the nervous -,
endocrine -, and immune systems form a regulatory network, which is fundamental
to the normal development and function of individuals from conception till
death. This regulatory system also plays a role in host protection against
pathological insults and in regeneration and healing. Therefore, the application
of the term Neuroimmune Biology to define this multi-disciplinary and integrative
science is fully justified.
ACKNOWLEDGEMENTS:
I owe
special homage to Hans Selye, who was my teacher and sparked my interest
in neuroimmune interaction. Over the years many colleagues collaborated/contributed
to the acquisition of the knowledge and ideas presented in this paper.
I owe special thanks to Drs. Andor Szentivanyi, Eva Nagy, Henry Friesen,
Kalman Kovacs, Dwight Nance, Donna Chow, Robert Shiu, Edward Baral, Richard
Warrington, Lorand Bertok, John Kellen and Sylvia Asa in this respect.
The experimental work discussed in this article was supported in part by
MRC of Canada, The Arthritis Society of Canada, The Manitoba Health Research
Council, The Manitoba Medical Services Foundation, Cancer Care Manitoba
and Orion-Pharmos Corporation of Finland. I am indebted to Carol Funk and
Valentina Tautkus for their devoted work on this manuscript.
|
TO
visit Elsevier's web site for more information on Neuroimmune
Biology
and
for information on how to purchase your copy of :
The
NEUROIMMUNE BIOLOGY BOOK SERIES
Elsevier
Science
|
REFERENCES
 |
[1] |
Sternberg
EM. The Balance Within: The Science Connecting Health and Emotions.New
York: WH Freeman and Company, 2000. |
 |
[2] |
Thompson
WG. Placebos: A review of the placebo response. Am J Gastroenterol 2000;95(
7):1637-43. |
 |
[3] |
Nowotny
A. In: Nowotny, editor. Beneficial effects of endotoxins. New York, Plenum
Press, 1993;1-55. |
 |
[4] |
Hammar
JA. The new views as to the morphology of the thymus gland and their bearing
on the problem of the function of the thymus. Endocrinology 1921;5:543-73,
731-60. |
 |
[5] |
Smith
PE. Effects of hypophysectomy upon the involution of the thymus in the
rat. Anat Rec 1930; 47:119-29. |
 |
[6] |
Selye
H. A syndrome produced by diverse nocuous agents. Nature (Lond) 1936;138:32. |
 |
[7] |
Selye
H. Thymus and adrenals in the response of the organism to injuries and
intoxication. Brit J Exp Path 1936; 17:234-248. |
 |
[8] |
Selye
H. Morphological changes in the fowl following chronic overdosage with
various steroids. J Morph 1943;73:401-421. |
 |
[9] |
Selye
H. The general adaptation syndrome and the diseases of adaptation. J Clin
Endocrinology 1946;6: 117-230. |
 |
[10] |
Selye
H. Effect of ACTH and cortisone upon an "anaphylactoid reaction". Can Med
Assoc J 1949;61: 553-556. |
 |
[11] |
Selye
H. Stress and disease. Science 1955;122:625-31. |
 |
[12] |
Selye
H. The Mast Cells. Washington: Butterworth, 1965. |
 |
[13] |
Filipp
G, Szentivanyi A, Mess B. Anaphylaxis and nervous system. Acta Med Hung
1952;2:163-73. |
 |
[14] |
Szentivanyi
A, Filipp G. Anaphylaxis and the nervous system. Part II. Ann Allergy 1958;16:143-151. |
 |
[15] |
Filipp
G, Szentivanyi A. Anaphylaxis and the nervous system. Part III. Allergy
1958;16: 306-11. |
 |
[16] |
Szentivanyi
A, Szekely J. Effect of injury to, and electrical stimulation of, hypothalamic
areas on anaphylactic and histamine shock of the guinea pig. A preliminary
report. Ann
Allergy
1956;14:259-261. |
 |
[17] |
Townley
RG, Trapani IL, Szentivanyi A. Sensitization to anaphylaxis and to some
of its pharmacological mediators by blockade of the beta adrenergic receptors.
J Allergy 1967;39( 3):177-79. |
 |
[18] |
Szentivanyi
A. The beta adrenergic theory of the atopic abnormality in bronchial asthma.
J Allergy 1968;42:203-32. |
 |
[19] |
Szentivanyi
A, Szentivanyi J, Wagner H. Measurement of numbers of adrenoceptors in
lymphocytes and lung tissue of patients with reversible obstructive airways
disease.
Clin
Pharmacol Ther 1980;27:193-206. |
 |
[20] |
Szentivanyi
A. The conformational flexibility of adrenoceptors and the constitutional
basis of atopy. Triangle 1979;18( 4):109-15. |
 |
[21] |
Szentivanyi
A, Heim O, Schultze P. Changes in adrenoceptor densities in membranes of
lung tissue and lymphocytes from patients with atopic disease. Ann NY Acad
Sci 1979;332:295-298. |
 |
[22] |
Szentivanyi
A. La flexibilite de conformation des adrenocepteurs et la base constitutionelle
du terrain allergique. Rev Franc Allergol 1979;19:205-214. |
 |
[23] |
Szentivanyi
A, Fitzpatrick DF. The altered reactivity of the effector cells to antigenic
and pharmacological influences and its relation to cyclic nucleotides.
II. Effector reactivities in the efferent loop of the immune response.
In: Filipp G, editor. Pathomechanismmus und Pathogenese Allergischer Reaktionen.
Werk-Verlag Dr. Edmund Banachewski,
Grafelfing
bei Munchen 1980;511-580. |
 |
[24] |
Szentivanyi
A, Polson JB, Krzanowski JJ. The altered reactivity of the effector cells
to antigenic and pharmacological influences and its relation to cyclic
nucleotides. I. Effector reactivities in the efferent loop of the immune
response. In: Filipp G, editor. Pathomechanismus und Pathogenese Allergischer
Reaktionen. Werk-Verlag, Dr. Edmund Banachewski, Grafelfing bei Munchen
1980; 460-510. |
 |
[25] |
Szentivanyi
A, Krzanowski JJ, Polson JB, Anderson WH. Evolution of research strategy
in the experimental analysis of the beta adrenergic approach to the constitutional
basis of atopy. In: Oehling A, Mathov E, Glazer I, Arbesman C, editors.
Advances in Allergology and Clinical Immunology. Oxford, Pergamon Press,
1980;301-308. |
 |
[26] |
Szentivanyi
A. Effect of bacterial products and adrenergic blocking agents on allergic
reactions. In: Samter M, Talmage DW, Rose B, Sherman WB, Vaughan JH, editors.
Textbook
of Immunological Diseases. Boston, MA: Little, Brown and Co. 1971;356-374. |
 |
[27] |
Szentivanyi
A, Krzanowski JJ, Polson JB. The autonomic nervous system: Structure, function,
and altered effector responses. In: Middleton E, Reed CE, Ellis EF, editors.
Allergy:
Principles and Practice. St. Louis, MO, The CV Mosby Co, 1978;256-300. |
 |
[28] |
Szentivanyi
A, Williams JF. The constitutional basis of atopic disease. In: Bierman
CW, Pearlman DS, editors. Allergic Diseases of Infancy, Childhood, and
Adolescence.
Philadelphia,
PA, WB Saunders Co1980;173-210. |
 |
[29] |
Szentivanyi
A. Adrenergic and cholinergic receptor studies in human lung and lymphocytic
membranes and their relation to bronchial hyperreactivity in asthma. In:
Patient Care Publications. Darien, CT, 1982;175-92. |
 |
[30] |
Hackney
JF, Szentivanyi A. The specificity of glucocorticoids in the relaxation
of respiratory smooth muscle in vitro. J Allergy Clin Immunol 1975;55:123.
(abstract). |
 |
[31] |
Hackney
JF, Szentivanyi A. The unique action of glucocorticoid succinates on respiratory
smooth muscle in vitro. The Pharmacologist 1975;17:271. (abstract). |
 |
[32] |
Lowitt
S, Szentivanyi A, Williams JF. Endotoxin inhibition of dexamethasone induction
of tryptophan oxygenase in suspension culture of isolated rat parenchymal
cells. II.
Effect
of in vivo pretreatment of rats with endotoxin. Biochem Pharmacol 1982;31:3403-3406. |
 |
[33] |
Szentivanyi
A, Szentivanyi J. Mechanisms of action of corticosteroids. In: Proceedings
of the International Symposium on Allergy and Immunology. Lima, Peru, 1985;
531-534. |
 |
[34] |
Korneva
EA, Khai LM. Effect of destruction of hypothalamic areas on immunogenesis.
Fed Proc 1964;23: T88. |
 |
[35] |
Jancso
N. Role of the nerve terminals in the mechanism of inflammatory reactions.
Bull. Millard Fillmore Hosp (Buffalo NY) 1960;7-53. |
 |
[36] |
Jancso
N. Desensitization with capsaicin and related acylamides as tool for studying
the function of pain receptors. In: RKS Lim, editor. Pharmacology of Pain.
Oxford, Pergamon Press, 1968. |
 |
[37] |
Dougherty
TF. Effect of hormones on lymphatic tissue. Physiol Rev 1952;32:379-407. |
 |
[38] |
Nagy
E, Berczi I. Immunodeficiency in hypophysectomized rats. Acta Endocrinology
1978;89:530-537. |
 |
[39] |
Berczi
I, Nagy E, Kovacs K, Horvath E. Regulation of humoral immunity in rats
by pituitary hormones. Acta Endocrinology 1981;98:506-513. |
 |
[40] |
Nagy
E, Berczi I, Friesen HG. Regulation of immunity in rats by lactogenic and
growth hormones. Acta Endocrinology 1983;102:351-357. |
 |
[41] |
Nagy
E, Berczi I, Wren GE, Asa SL, Kovacs K. Immunomodulation by bromocriptine.
Immunopharmacology 1983;6:231-243. |
 |
[42] |
Berczi
I (author/ editor). Pituitary Function and Immunity (with 12 contributing
authors). Monograph published by: CRC Press, Inc., Boca Raton, FL, 1986. |
 |
[43] |
Wannemacher
RW Jr, Pekarek RS, Thompson WL, et al. A protein from polymorphonuclear
leukocytes (LEM) which affects the rate of hepatic amino acid transport
and synthesis of acute-phase globulins. Endocrinology 1975;96: 651-661. |
 |
[44] |
Besedovsky
HO, del Rey A, Sorkin E. lymphokine-containing supernatants from Con A-stimulated
cells increase corticosterone blood levels. J Immunol 1981; 126:385-7. |
 |
[45] |
Berkenbosch
F, van Oers J, del Rey A, Tilders F, Besedovsky H. Corticotropin-releasing
factor-producing neurons in the rat activated by interleukin-1. Science
1987; 238:524-526. |
 |
[46] |
Sapolsky
R, Rivier C, Yamamoto G, Plotsky P, Vale W. Interleukin-1 stimulates the
secretion of hypothalamic corticotropin-releasing factor. Science 1987;238:522-524. |
 |
[47] |
Nakamura
H, Motoyoshi S, Kadokawa T. Anti-inflammatory action of interleukin 1 through
the pituitary-adrenal axis in rats. Eur J Pharmacol 1988;141:67-73. |
 |
[48] |
Uehara
A, Gottschall PE, Dahl RR, Arimura A. Interleukin-1 stimulates ACTH release
byan indirect action which requires endogenous corticotropin releasing
factor. Endocrinology 1987;121:1580-1582. |
 |
[49] |
Bernton
EW, Beach JE, Holaday JW, Smallridge RC, Fein HG. Release of multiple hormones
by a direct action of interleukin-1 on pituitary cells. Science 1987;238:519-521. |
 |
[50] |
McCann
SM, Karanth S, Kamat A, Les Dees W, Lyson K, Gimeno M, Rettori V.Induction
by cytokines of the pattern of pituitary hormone secretion in infection.
Neuroimmunomodulation 1994;1:13. |
 |
[51] |
Pletsityi
DF, Averi'anova LL. The influence of vagotomy on the development of experimental
endocarditis. Dokl Akad Nauk SSSR 1966; Mar 1;167( 1):238-40. Russian |
 |
[52] |
Williams
JM, Petersen RG, Shea PA, Schemdtje JF, Bauer DC, Felten DL. Sympathetic
innervation of murine thymus and spleen: evidence for a functional link
between the nervous and immune systems. Brain Res Bull 1981;
Jan;
6( 1):83-94. |
 |
[53] |
Nance
DM. Innervation of the spleen in the rat: evidence for absence of afferent
innervation. Burns J Brain Behav Immun 1989; Dec; 3( 4):281-90. |
 |
[54] |
Fleshner
M, Goehler LE, Hermann J, Relton JK, Maier SF, Watkins LR. Interleukin-1beta
induced corticosterone elevation and hypothalamic NE depletion is vagally
mediated. Brain Res Bull 1995;37( 6):605-10. |
 |
[55] |
Metal'nikov
S, Chorine V. Roles des refl exes conditionels dans l'immunite. Ann Inst
Pasteur 1926;40:893-900. |
 |
[56] |
Smith
GH, Salinger R. Hypersensitivity and the conditioned refl ex. Yale J Biol
Med 1933;5:387-402. |
 |
[57] |
Ader
R. Letter: Behaviorially conditioned immunosuppression. Psychosom Med 1974;36(
2): 183-184. |
 |
[58] |
MacQueen
G, Marshall J, Perdue M, Siegel S, Bienenstock J. Pavlovian conditioning
of rat mucosal mast cells to secrete rat mast cell protease II. Science
1989;243:83-85. |
 |
[59] |
Gorczynski
RM, Macrae S, Kennedy M. Conditioned immune response associated with allogeneic
skin grafts in mice. J Immunol 1982;129:704-9. |
 |
[60] |
Johnson
HM, Smith EM, Torres BA, Blalock JE. Regulation of the in vitro antibody
response by neuroendocrine hormones. Proc Nat Acad Sci USA 1982;Sci 79:4171-4. |
 |
[61] |
Montgomery
DW, Zukoski CF, Shah GN, Buckley AR, Pacholczyk T, Russell DH. Concanavalin
A-stimulated murine splenocytes produce a factor with prolactin-like bioactivity
and immunoreactivity. Biochem Biophys Res Commun 1987; Jun 15;145( 2):692-8. |
 |
[62] |
DiMattia,
Gellersen B, Duckworth ML, Friesen HG. Human prolactin gene expression.
The use of an alternative noncoding exon in decidua and the IM-9-P3 lymphoblast
cell
line.
J Biol Chem 1990; Sept 25; 265( 27): 16412-21. |
 |
[63] |
Salamonsen
LA, Woolley DE. Menstruation: induction by matrix metalloproteinases and
inflammatory cells. J Reprod Immunol 1999; Sept;44( 1-2):1-27. |
 |
[64] |
Kim
HG, Kassis J, Souto JC, Turner T, Wells A. EGF receptor signaling in prostate
morphogenesis and tumorigenesis. Histol Histopathol 1999;Oct;14( 4):1175-82. |
 |
[65] |
Bodey
B, Bodey B Jr, Siegel SE, Kaiser HE. Molecular biological ontogenesis of
the thymic reticulo-epithelial cell network during the organization of
the cellular
microenvironment.
In Vivo. 1999; May-Jun;13( 3):267-94. |
 |
[66] |
Bianco
P, Riminucci M, Kuznetsov S, Robey PG. Multipotential cells in the bone
marrow stroma: regulation in the context of organ physiology. Crit Rev
Eukaryot Gene Expr 1999;9( 2):159-73. |
 |
[67] |
Robinson
GW, Karpf AB, Kratochwil K. Regulation of mammary gland development by
tissue interaction. J Mammary Gland Biol Neoplasia 1999; Jan; 4( 1):9-19. |
 |
[68] |
Maeurer
MJ, Lotze MT. Interleukin-7 (IL-7) knockout mice. Implications for lymphopoiesis
and organ-specific immunity. Int Rev Immunol 1998;16( 3-4):309-22. |
 |
[69] |
Fidler
IJ. Angiogenesis and cancer metastasis. Cancer J Sci Am 2000; Apr; 6 Suppl
2:S134-41. |
 |
[70] |
King
A. Uterine leukocytes and decidualization. Hum Reprod Update 2000; Jan-Feb;6(
1):28-36. |
 |
[71] |
Wagner
JG, Roth RA. Neutrophil migration mechanisms, with an emphasis on the pulmonary
vasculature. Pharmacol Rev 2000; Sept;52( 3):349-74. |
 |
[72] |
Pirtskhalaishvili
G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate
cancer progression. Prostate 2000; Jun 15;44( 1):77-87. |
 |
[73] |
Tanaka
Y. Integrin activation by chemokines: relevance to infl ammatory adhesion
cascade during T cell migration. Histol Histopathol 2000; Oct;15( 4):1169-76. |
 |
[74] |
Alford
D, Taylor-Papadimitriou J. Cell adhesion molecules in the normal and cancerous
mammary gland. J Mammary Gland Biol Neoplasia 1996; Apr;1( 2):207-18. |
 |
[75] |
Kimber
SJ, Spanswick C. Blastocyst implantation: the adhesion cascade. Semin Cell
Dev Biol 2000; Apr;11( 2): 77-92. |
 |
[76] |
Shiosaka
S, Yoshida S. Synaptic microenvironments -- structural plasticity, adhesion
molecules, proteases and their inhibitors. Neurosci Res 2000; Jun;37( 2):85-9. |
 |
[77] |
Renard
V, Cambiaggi A, Vely F, Blery M, Olcese L, Olivero S, Bouchet M, Vivier
E. Transduction of cytotoxic signals in natural killer cells: a general
model of fine tuning between activatory and inhibitory pathways in lymphocytes.
Transplant Rev 1997;155:205-221. |
 |
[78] |
Daëron
M. Fc receptor biology. Annu. Rev Immunol 1997; 15:203-34. |
 |
[79] |
Isakov
N. Immunoreceptor thyrosine-based activation motif (ITAM), a unique module
linking antigen and Fc receptors to their signaling cascades. J Leukoc
Biol 1997; 61:6-16. |
 |
[80] |
Venters
HD, Tang Q, Liu Q, VanHoy RW, Dantzer R, Kelley KW. A new mechanism of
neurodegeneration: a proinflammatory cytokine inhibits receptor signaling
by a survival peptide. Proc Natl Acad Sci USA 1999; Aug 17;
96(
17):9879-84. |
 |
[81] |
Yee
D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens
in breast cancer. J Mammary Gland Biol Neoplasia 2000; Jan; 5( 1):107-15. |
 |
[82] |
Kawashima
K, Fujii T. Extraneuronal cholinergic system in lymphocytes. Pharmacol
Ther 2000; Apr; 86( 1):29-48. |
 |
[83] |
Ptasznik
A, Gewirtz AM. Crosstalk between G protein - coupled receptors and tyrosine
kinase signaling: Src take centre stage. Arch Immunol Ther Exp (Warsz)
2000;48( 1):27-30. |
 |
[84] |
Bornfeldt
KE, Krebs EG. Crosstalk between protein kinase A and growth factor receptor
signaling pathways in arterial smooth muscle. Cell Signal 1999; Jul; 11(
7):465-77. |
 |
[85] |
Folli
F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR. Crosstalk
between insulin and angiotensin II signalling systems. Exp Clin Endocrinol
Diabetes 1999; 107( 2):133-9. |
 |
[86] |
Paul
WE. The immune system: An introduction. In: Paul WE, editor. Fundamental
Immunology, 4th edition. Lippincott-Raven, 1999;1-35. |
 |
[87] |
Clevenger
CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells
of the immune system. J Endocrinol 1998;157:187-197. |
 |
[88] |
Chang
L, Crowston JG, Cordeiro MF, Akbar AN, Khaw PT. The role of the immune
system in conjunctival wound healing after glaucoma surgery. Surv Ophthalmol
2000;
Jul-Aug;45(
1):49-68. |
 |
[89] |
Schwartz
M, Cohen IR. Autoimmunity can benefit self-maintenance. Immunol Today 2000;
Jun; 21( 6):265-8. |
 |
[90] |
Neumann
H. The immunological microenvironment in the CNS: implications on neuronal
cell death and survival. J Neural Transm Suppl 2000;59:59-68. |
 |
[91] |
Havran
WL. A role for epithelial gammadelta T cells in tissue repair. Immunol
Res 2000;21( 2-3):63-9. |
 |
[92] |
Antel
J. Regulation of the Immune Response within the Central Nervous System.
In:Berczi I, Gorczynski R, editors. Neuroimmune Biology: New Foundation
of Biology.
Shannon,
Co. Clare, Ireland, Elsevier, 2001. |
 |
[93] |
Stevens-Felten
SY, Bellinger DL. Noradrenergic and peptidergic innervation of lymphoid
organs. Chem Immunol 1997;69:99-131. |
 |
[94] |
Nance
D. Immunoregulation by the sympathetic nervous system. In: Berczi I, Gorczynski
R, editors. Neuroimmune Biology: New Foundation of Biology. Shannon, Co.
Clare, Ireland, Elsevier, 2001 |
 |
[95] |
McKay
DM, Bienenstock J. The interaction between mast cells and nerves in the
gastrointestinal tract. Immunology Today 1994;15:533-538. |
 |
[96] |
Derijk
RH, Strijbos PJ, van Rooijen N, Rothwell NJ, Berkenbosch F. Fever and thermogenesis
in response to bacterial endotoxin involve macrophage-dependent
mechanisms
in rats. Am J Physiol 1993 Nov 265( 5 Pt 2): R1179-83. |
 |
[97] |
Berczi
I, Nagy E. Immune-endocrine interactions. In: Stefaneanu L, Sasano H, Kovacs
K, editors. Molecular and Cellular Endocrine Pathology. Chapman and Hall,
2000: 425-456. |
 |
[98] |
Moldofsky
H. Sleep, health and immunocompetence. In: Berczi I, Gorczynski RM, editors.
Neuroimmune Biology: New Foundation of Biology. Shannon, Co. Clare, Ireland,
Elsevier,
2001 |
 |
[99] |
Müller
EE, Salerno F, Cocchi D, et al. Interaction between the thyrotropin releasing
hormone-induced growth hormone rise and dopaminergic drugs: Studies in
pathological
conditions
in the animal and man. Clin Endocrinol 1979; 11: 645-56. |
 |
[100] |
Van
den Berghe G, de Zegher F, Vlasselaers D, Schetz M, Verwaest C, Ferdinande
P, Lauwers P. Thyrotropin - releasing hormone in critical illness: From
a dopamine - dependent test to a strategy for increasing low serum triiodothyronine,
prolactin, and growth hormone concentrations. Crit Care Med 1996;24:590-5. |
 |
[101] |
Li
S, Crenshaw EB III, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG. Dwarf
locus mutants lacking three pituitary cell types result from mutations
in the POU-domain gene pit-1. Nature 1990;347:528-33. |
 |
[102] |
Castro
PR, Penalva R, Pereda MP, Renner U, Reul JMHM, Stalla GK, Holsboer F, Arzt
E.Early activation of thyrotropin-releasing-hormone and prolactin plays
a critical role duringa T cell-dependent immune response. Endocrinology
1999;140:690-97. |
 |
[103] |
Raiden
S, Polack E, Nahmod V, Labeur M, Holsboer F, Larzt E. TRH receptor on immune
cells: in vitro and in vivo stimulation of human lymphocyte and rat splenocyte
DNA
synthesis
by TRH. J Clin Immunol 1995;15:242-9. |
 |
[104] |
Wang
J, Klein JR. Thymus-neuroendocrine interactions in extrathymic T cell development.
Science 1994;265:1860-1862. |
 |
[105] |
Komorowski
J, Zylinska K, Pawlikowski M, Stepien H. Stimulatory effect of thyrotropin
(TSH) on interleukin-2 (IL-2) release from human peripheral blood lymphocytes.
A
dose-response study in vitro. Hormones Metab Res 1993;25:598-599. |
 |
[106] |
Nicoll
CS. Prolactin and growth hormone: Specialists on one hand and mutual mimics
on the other. Perspect Biol Med 1982;25:369-381. |
 |
[107] |
Berczi
I. The immunology of prolactin. Semin Reprod Endocrinology 1992;10:196-219. |
 |
[108] |
Lewis
UJ. Growth hormone -What is it and what does it do. Trends Endocrinol Metab
1992;3:117-121. |
 |
[109] |
Southard
JN, Talamantes F. Placental prolactin-like proteins in rodents -Variations
on a structural theme. Mol Cell Endocrinology 1991;79:C133-140. |
 |
[110] |
Nickel
BE, Kardami E, Cattini PA. The human placental growth hormone variant is
mitogenic for rat lymphoma Nb2 cells. Endocrinology 1990;126:971-976. |
 |
[111] |
Duckworth
ML, Robertson MC, Schroedter IC, Szpirer C, Friesen HG. Molecular genetics
and biology of the rat placental prolactin family. In: Soares MJ, Handwerger
S, Talamantes F, editors. Trophoblast cells: pathways for maternal-embryonic
communication. New York: Springer, 1993;169-190. |
 |
[112] |
Berczi
I, Chalmers IM, Nagy N, Warrington RJ. The immune effects of neuropeptides.Bailliere
Clin Rheumatol 1996;10:227-257. |
 |
[113] |
Rohn
WM, Weigent DA. Cloning and nucleotide sequencing of rat lymphocyte growth
hormone cDNA. Neuroimmunomodulation 1995;2:108-14. |
 |
[114] |
Palmetshofer
A, Zechner D, Luger TA, Barta A. Splicing variants of the human growth
hormone mRNA: detection in pituitary, mononuclear cells and dermal fibroblasts.
Mol
Cell
Endocrinology 1995;113:225-34. |
 |
[115] |
Sabharwal
P, Varma S. Growth hormone synthesized and secreted by human thymocytes
acts via insulin-like growth factor I as an autocrine and paracrine growth
factor. J Clin Endocrinol Metab 1996;81:2663-9. |
 |
[116] |
Matera
L. Endocrine, paracrine and autocrine actions of prolactin on immune cells.
Life Sci 1996;59:599-614. |
 |
[117] |
Kelly
PA, Djiane J, Postel-Vinay MC, Edery M. The prolactin/ growth hormone receptor
family. Endocr Rev 1991;12:235-251. |
 |
[118] |
Wells
JA, de Vos AM. Structure and function of human growth hormone: Implications
for the hematopoietins. Annu. Rev Biophys. Biomol Struct. 1993;22:329-351. |
 |
[119] |
Kishimoto
T, Taga T, Akira S. Cytokine signal transduction. Cell 1994;76:253-262. |
 |
[120] |
Ihle
JN. The Janus kinase family and signaling through members of the cytokine
receptor superfamily. Proc Soc Exp Biol Med 1994;206:268-72. |
 |
[121] |
Rui
H, Djeu JY, Evans GA, Kelley PA, Farrar WL. Prolactin receptor triggering:
Evidence for rapid tyrosine kinase activation. J Biol Chem. 1992;267:24076-24081. |
 |
[122] |
Clevenger
CV, Sillman AL, Prystowsky MB. Interleukin-2 driven nuclear translocation
of prolactin in cloned lymphocytes-T. Endocrinology 1990;127:3151-3159. |
 |
[123] |
Horseman
ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones:
growth hormone, prolactin, and hematopoietic cytokines. Endocrine Rev 1994;15:627-649. |
 |
[124] |
Berczi
I. Pituitary hormones and immune function, Acta Paediatr. (Suppl) 1997;423:70-75. |
 |
[125] |
Potter
EL, Craig JM. Pathology of the Fetus and the Infant. 3rd edition. Chicago,
Year Book, 1975. |
 |
[126] |
Arezzini
C, De Gori V, Tarli P, Neri P. Weight increase of body and lymphatic tissues
in dwarf mice treated with human chorionic somatomammotropin (HCS). Proc
Soc Exp Biol Med 1972;141:98-100. |
 |
[127] |
Berczi
I, Nagy E. Human placental lactogen is a hemopoietic hormone. Br J Haematol.
1991;79:355-358. |
 |
[128] |
Berczi
I, Nagy E. The effect of prolactin and growth hormone on hemolymphopoietic
tissue and immune function. In: Berczi I, Kovacs K, editors. Hormones and
Immunity. Lancaster, England, MTP Press, 1987;145-171. |
 |
[129] |
Berczi
I. The role of the growth and lactogenic hormone family in immune function.
Neuroimmunomodulation. 1994;1:201-216. |
 |
[130] |
Bellone
G, Geuna M, Carbone A, Silvestri S, Foa R, Emanuelli G, et al. Regulatory
actionof prolactin on the in vitro growth of CD34+ ve human hemopoietic
progenitor cells. J Cell Physiol 1995;163:221-31. |
 |
[131] |
Merchav
S, Tatarsky I, Hochberg Z. Enhancement of erythropoiesis in vitro by human
growth hormone is mediated by insulin-like growth factor-I. Br J Haematol
1988;70:267-271. |
 |
[132] |
Merchav
S, Tatarsky I, Hochberg Z. Enhancement of human granulopoiesis in vitro
by biosynthetic insulin-like growth factor I/ somatomedin C and human growth
hormone.
J.
Clin. Invest 1988;81:791-797. |
 |
[133] |
Kelley
KW, Arkins S, Minshall C, Liu Q, Dantzer R. Growth hormone, growth factors
and hematopoiesis. Hormone Res 1996;45:38-45. |
 |
[134] |
Kelley
KW, Brief S, Westly HJ, Novakofski J, Bechtel PJ, Simon J, Walker EB. GH
3 pituitary adenoma cells can reverse thymic aging in rats. Proc Natl Acad
Sci USA
1986;83:5663-5667. |
 |
[135] |
Berczi
I, Nagy E, De Toledo SM, Matusik RJ, Friesen HG. Pituitary hormones regulate
c-myc and DNA synthesis in lymphoid tissue. J Immunol 1991;146:2201-2206. |
 |
[136] |
Beschorner
WE, Divic J, Pulido H, Yao X, Kenworthy P, Bruce G. Enhancement of thymic
recovery after cyclosporine by recombinant human growth hormone and insulin-like
growth factor-I. Transplantation 1991;52:879-884. |
 |
[137] |
Binz
K, Joller P, Froesch P, Binz H, Zapf J, Froesch ER. Repopulation of the
atrophied thymus in diabetic rats by insulin-like growth factor I. Proc
Natl Acad Sci USA 1990;87:3690-3694. |
 |
[138] |
Timsit
J, Savino W, Safi eh B, Chanson P, Gagnerault MC, Bach JF, Dardenne M.
Growth hormone and insulin-like growth factor-I stimulate hormonal function
and proliferation of thymic epithelial cells. J Clin Endocrinol Metab 1992;75:183-188. |
 |
[139] |
Kaplan
SL, Grumbach MM, Friesen HG, Costom BH. Thyrotropin-releasing factor (TRF)
effect on secretion of human pituitary prolactin and thyrotropin in children
and
in
idiopathic hypopituitary dwarfi sm: further evidence for hypophysiotropic
hormone deficiencies. J Clin Endocrinol Metab 1972;35:825-830. |
 |
[140] |
Spangelo
BL, Hall NRS, Ross PC, Goldstein AL. Stimulation of in vivo antibody production
and concanavalin-A-induced mouse spleen cell mitogenesis by prolactin.
Immunopharmacology 1987;14:11-20. |
 |
[141] |
Cross
RJ, Campbell JL, Markesbery WR, Roszman TL. Transplantation of pituitary
grafts fail to restore immune function and to reconstitute the thymus glands
of aged mice. Mech Age Dev 1990;56:11-22. |
 |
[142] |
Cesano
A, Oberholtzer E, Contarini M, Geuna M, Bellone G, Matera L. Independent
and synergistic effect of interleukin-2 and prolactin on development of
T-and NK-derived LAK effectors. Immunopharmacology 1994;28:67-75. |
 |
[143] |
Bozzola
M, Valtorta A, Moretta A, Cisternino M, Biscaldi I, Schimpff RM. In vitro
and in vivo effect of growth hormone on cytotoxic activity. J Pediat1990;117:596-599. |
 |
[144] |
Rovensky
J, Ferencikova J, Vigas M, Lukac P. Effect of growth hormone on the activity
of some lysosomal enzymes in neutrophilic polymorphonuclear leukocytes
of hypopituitary dwarfs. Int J Tissue React 1985;7:153-159. |
 |
[145] |
Wiedermann
CJ, Niedermuhlbichler M, Beimpold, Braunsteiner H. In vitro activation
of neutrophils of the aged by recombinant human growth hormone. J Infect
Dis 1991;
164:1017-1020. |
 |
[146] |
Manfredi
R, Tumietto F, Azzaroli L, Zucchini A, chiodo F, Manfredi G. Growth hormone
(GH) and the immune system: impaired phagocytic function in children with
idiopathic GH deficiency is corrected by treatment with biosynthetic GH.
J Pediat Endocrinol 1994;7:245-251. |
 |
[147] |
Cecilia-Fornari
M, Fernanda-Palacios M, Diez RA, Intebi AD. Decreased chemotaxis of neutrophils
in acromegaly and hyperprolactinemia. Eur J Endocrinology 1994;130:
463-468. |
 |
[148] |
Rapaport
R. Immunomodulation by growth hormone in humans. In: Berczi I, Szelenyi
J, editors. Advances in Psychoneuroimmunology. New York: Plenum Press,
1994:83-98. |
 |
[149] |
Galdiero
M, Donnarumma G, Cipollareo de l'Ero G, Marcatili A, Scarfogliero P, Sommese
L. Effect of growth hormone, prolactin and insulin on the release of IL-1
alpha,
IFN-gamma and IL-4 by staphylococcal enterotoxin A-stimulated splenocytes.
Eur Cytokine Netw 1995;6:187-94. |
 |
[150] |
LeRoith
D, Yanowski J, Kaldjian EP, Jaffe ES, LeRoith T, Purdue K, Cooper BD, Pyle
R, Adler W. The effects of growth hormone and insulin-like growth factor
I on the immune system of aged female monkeys. Endocrinology 1996;137:1071-9. |
 |
[151] |
Gelato
MC. Aging and immune function: a possible role for growth hormone. Hormone
Res 1996;45:46-9. |
 |
[152] |
Dorshkind
K, Horseman ND. The roles of prolactin, growth hormone, insulin-like growth
factor-I, and thyroid hormones in lymphocyte development and function.
Insights from genetic models of hormone and hormone receptor deficiency.
Endocrine Rev 2000; 21:292-312. |
 |
[153] |
Bole-Feysot
C, Goffi n V, Edery M, Binart N and Kelly PA. Prolactin (PRL) and its receptor:
Actions, signal transduction pathways and phenotypes observed in PRL-receptor
knockout mice. Endocrine Rev 1998;19:225-68. |
 |
[154] |
Nagy
E, Berczi I. Hypophysectomized rats depend on residual prolactin for survival.
Endocrinology 1991;146:2776-2784. |
 |
[155] |
Komorowski
J, Stepien H, Pawlikowski M. The evidence of thyroliberin/ triiodothyronine
control of TSH secretory response from human peripheral blood monocytes
cultured in vitro. Neuropeptides 1993;25:31-4. |
 |
[156] |
Bagriacik
EU, Klein JR. The thyrotropin (thyroid-stimulating hormone) receptor is
expressed on murine dendritic cells and on a subset of CD45RBhigh lymph
node T cells:
functional
role for thyroid-stimulating hormone during immune activation. J Immunol
2000;Jun 15;164( 12): 6158-65. |
 |
[157] |
Hsu
J-H, Brent GA. Thyroid hormone receptor gene knock outs. Trends Endocrinol
Metab 1998;9:103-111. |
 |
[158] |
Fabris
N, Mocchegiani E, Provinciali M. Pituitary-thyroid axis and immune system:
a reciprocal neuroendocrine - immune interaction. Hormone Res 1995;43:29-38. |
 |
[159] |
Berczi
I. The influence of pituitary-adrenal axis on the immune system. In: Berczi
I, editor. Pituitary Function and Immunity. Boca Raton, Florida, CRC Press,
1986:49-132. |
 |
[160] |
Besedovsky
HO, del Rey A, Klusman I, Furukawa H, Monge-Arditi G, Kabiersch A. Cytokines
as modulators of the hypothalamus-pituitary-adrenal axis. J Steroid Biochem.
Mol
Biol 1991;40:613-618. |
 |
[161] |
Vamvakopoulos
NC, Chrousos GP. Hormonal regulation of human corticotropin-releasing hormone
gene expression: implications for the stress response and immune/ inflammatory
reaction. Endocrine Rev 1994;15:409-420. |
 |
[162] |
Heijnen
CJ, Zijlstra J, Kavelaars A, Croiset G, Ballieux RE. Modulation of the
immune response by POMC-derived peptides. I. Influence on proliferation
of human lymphocytes.
Brain
Behav Immun 1987;1:284-291. |
 |
[163] |
Catania
A, Airaghi L, Colombo G, Lipton JM. Alpha-Melanocyte-stimulating Hormone
in
Normal Human Physiology and Disease States. Trends Endocrinol Metab 2000;
Oct 1;11( 8):304-308. |
 |
[164] |
Stein
C, Schafer M, Hassan AHS. Peripheral opioid receptors. Ann Med 1995;27:219-221. |
 |
[165] |
Taub
DD, Eisenstein TK, Geller EB, Adler MW, Rogers TJ. Immunomodulatory activity
of µ-and -selective opioid agonists. Proc Natl Acad Sci USA 1991;88:360-364. |
 |
[166] |
Alicea
C, Belkowski S, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of primary
murine macrophage cytokine production in vitro following treatment with
the -opioid
agonist
U50, 488H. J Neuroimmunol 1996;64:83-90. |
 |
[167] |
Blalock
JE. Proopiomelanocortin and the immune - neuroendocrine connection. Ann
N Y Acad Sci 1999;Oct 20;885:161-72. |
 |
[168] |
Catania
A, Lipton JM. The neuropeptide alpha - melanocyte -stimulating hormone:
a key component of neuroimmunomodulation. Neuroimmunomodulation. 1994;
93-99. |
 |
[169] |
Shimizu
T, Streilein JW. Infl uence of alpha-melanocyte stimulating hormone on
induction of contact hypersensitivity and tolerance. J Dermatol Sci 1994;8:187-193. |
 |
[170] |
Grabbe
S, Bhardwaj RS, Mahnke K, Simon MM, Schwarz T, Luger TA. Alpha-melanocyte-stimulating
hormone induces hapten-specific tolerance in mice. J Immunol1996;156:473-478. |
 |
[171] |
King
LB, Vacchio MS, Dixon K, Hunziker R, Margulies DH, Ashwell JD. A targeted
glucocorticoid receptor antisense transgene increases thymocyte apoptosis
and alters
thymocyte
development. Immunity 1995;3:647-656. |
 |
[172] |
Wiegers
GJ, Labeur MS, Stec IEM, Klinkert WEF, Holsboer F, Reul JMHM. Glucocorticoids
accelerate anti-T cell receptor-induced T cell growth. J Immunol 1995;
155:1893-1902. |
 |
[173] |
Munck
A, Naray-Fejes-Toth A, Guyre PM. Mechanisms of glucocorticoid actions on
the immune system. In: Berczi I, Kovacs K, editors. Hormones and Immunity.
Lancaster,
England:
MTP Press Ltd, 1987. |
 |
[174] |
Vacchio
MS, Papadopoulos V, Ashwell JD. Steroid production in the thymus: implications
for thymocyte selection. J Exp Med 1994;179:1835-46. |
 |
[175] |
Rook
GA. Glucocorticoids and immune function. Baillieres Best Pract Res Clin
Endocrinol Metab 1999;Dec;13
(
4):567-81. |
 |
[176] |
Ashwell
JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function.
Annu. Rev Immunol 2000;18:309-45. |
 |
[177] |
Grasso
G, Massai L, De Leo V, Muscettola M. The effect of LHRH and TRH on human
interferon-gamma production in vivo and in vitro. Life Sci 1998;62( 22):2005-14. |
 |
[178] |
Athreya
BH, Pletcher J, Zulian F, Weiner DB, Williams WV. Subset-specifi c effects
of sex hormones and pituitary gonadotropins on human lymphocyte proliferation
in vitro.
Clin
Immunol ImmunoPathol 1993;66:201-211. |
 |
[179] |
Rouabhia
M, Chakir J, Deschaux P. Interaction between the immune and endocrine systems:
Immunodulatory effects of luteinizing hormone. Prog NeuroendocrinImmunol
1991;4:86-91. |
 |
[180] |
Komorowski
J, Stepien H. FSH and LH induce interleukin-6 (IL-6) release from human
peripheral blood monocytes cultures in vitro. A dose-response study. Hormone
Metab
Res
1994;26:438-439. |
 |
[181] |
Sullivan
DA. Endocrine regulation of the ocular secretory immune system. In: Berczi
I, Kovacs K, editors. Hormones and immunity. Lancaster, England, MTP Press,
1987: 54-92. |
 |
[182] |
Nelson
JL, Steinberg AD. Sex steroids, autoimmunity and autoimmune disease. In:
Berczi I, Kovacs, K, editors. Hormones and Immunity. Lancaster, England,
MTP Press,
1987:93-119. |
 |
[183] |
Nagy
E, Baral E, Berczi I. Immune System. In: Oettel M, editor-in-chief. Handbook
of Experimental Pharmacology. Estrogens and anti-estrogens. Section IV.
Physiology and
Pathophysiology
of estrogens. Springer-Verlag (in press). |
 |
[184] |
Lahita
RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin
Rheumatol 1999;Sept;11
(
5):352-6. |
 |
[185] |
Muller
D, Chen M, Vikingsson A, Hildeman D, Pederson K. Oestrogen influences CD4
+ T-lymphocyte activity in vivo and in vitro in 2-microglobulin-deficient
mice.
Immunology
1995;86:162-7. |
 |
[186] |
Ahmed
SA, Talal N, Christadoss P. Genetic regulation of testosterone-induced
immune suppression. Cell Immunol 1987;104( 1):91-98. |
 |
[187] |
Greenstein
BD, de Bridges EF, Fitzpatrick FTA. Aromatase inhibitors regenerate the
thymus in aging male rats. Int J Immunopharm 1992;14:541-53. |
 |
[188] |
Araneo
BA, Dowell T, Diegel M, Daynes RA. Dihydrotesterone exerts a depressive
influence on the production of interleukin-4 (IL-4), IL-5, and gamma -
interferon, but not IL-2 by activated murine T cells. Blood 1991;78:688-99. |
 |
[189] |
Konstadoulakis
MM, Syrigos KN, Baxevanis CN, Syrigou EI, Papamichail M, Peveretos P, Anapliotou
M, Golematis BC. Effect of testosterone administration, pre-and postnatally,
on the immune system of rats. Horm Metab Res 1995;27:275-8. |
 |
[190] |
Regelson
W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA) -the "mother steroid."
I. Immunologic action. Ann NY Acad Sci 719:553-63. |
 |
[191] |
Catania
RA, Angele MK, Ayala A, Cioffi WG, Bland KI, Chaudry IH. Dehydroepiandro-sterone
restores immune function following trauma-haemorrhage by a direct effect
on T lymphocytes. Cytokine 1999;Jun;11( 6):443-50. |
 |
[192] |
Padgett
DA, Loria RM. In vitro potentiation of lymphocyte activation by dehydroepiandro-sterone,
androstenediol, and androstenetriol. J Immunol 1994;153: 1544-52. |
 |
[193] |
Suzuki
T, Suzuki N, Daynes RA, Engleman EG. Dehydroepiandrosterone enhances IL2
production and cytotoxic effector function of human T cells. Clin Immunol
ImmunoPathol 1991;61:202-11. |
 |
[194] |
Weksler
ME. Immune senescence and adrenal steroids: immune dysregulation and the
action of dehydroepiandrosterone (DHEA) in old animals. Eur J Clin Pharmacol
1993;45:S21-3. |
 |
[195] |
Loria
RM, Padgett DA, Huynh PN. Regulation of the immune response by dehydroepiandro-sterone
and its metabolites. J Endocrinol 1996;150:S209-20. |
 |
[196] |
Check
JH, Tarquini P, Gandy P, Lauer C. A randomized study comparing the efficacy
of reducing the spontaneous abortion rate following lymphocyte immunotherapy
and progesterone treatment versus progesterone alone in primary habitual
aborters. Gynecol Obstet Invest 1995;39:257-61. |
 |
[197] |
Fleming
MW, Gamble HR. Consequences of dose-dependent immunosuppression by progesterone
on parasitic worm burdens in lambs. Am J Vet Res 1993;54:1299-302. |
 |
[198] |
Parr
MB, Kepple L, McDermott MR, Drew MD, Bozzola JJ, Parr EL. A mouse model
for studies of mucosal immunity to vaginal infection by herpes simplex
virus type 2.
Lab
Invest 1994;70:369-80. |
 |
[199] |
Kalo-Klein
A, Witkin SS. Regulation of the immune response to Candida albicans by
monocytes and progesterone. Am J Obstet Gynecol 1991;164:1351-4. |
 |
[200] |
Nohmi
T, Abe S, Dobashi K, Tansho S, Yamaguchi H. Suppression of anti-Candida
activity of murine neutrophils by progesterone in vitro: a possible mechanism
in pregnant
women's
vulnerability to vaginal Candidiasis. Microbiol Immunol 1995;39:405-9. |
 |
[201] |
Li
ZG, Danis VA, Brooks PM. Effect of gonadal steroids on the production of
IL-1 and IL-6 by blood mononuclear cells in vitro. Clin Exp Rheumatol 1993;11:157-62. |
 |
[202] |
Szekeres-Bartho
J, Barakonyi A, Polgar B, Par G, Faust Z, Palkovics T, Szereday The role
of gamma/ delta T cells in progesterone-mediated immunomodulation during
pregnancy: a review. Am J Reprod Immunol 1999;Jul;42( 1):44-8. |
 |
[203] |
Manolagas
SC, Yu XP, Girasole G, Bellido T. Vitamin D and the hematolymphopoietic
tissue: a 1994 update. Sem Nephrol 1994;14:129-43. |
 |
[204] |
Bouillon
R, Garmyn M, Verstuyf A, Segaert S, Casteels K, Mathieu C. Paracrine role
for calcitriol in the immune system and skin creates new therapeutic possibilities
for vitamin D analogs. Eur J Endocrinology 1995;133:7-16. |
 |
[205] |
Yang
S, Smith C, Prahl JM, Luo X, DeLuca HF. Vitamin D deficiency suppresses
cell-mediated immunity in vivo. Arch Biochem. Biophys. 1993;303:98-106. |
 |
[206] |
Piemonti
L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Allavena P, Di
Carlo V. Vitamin D3 affects differentiation, maturation, and function of
human monocyte-derived dendritic cells. J Immunol 2000;May 1;164( 9):4443-51. |
 |
[207] |
Daynes
RA, Enioutina EY, Butler S, Mu HH, McGee ZA, Araneo BA. Induction of common
mucosal immunity by hormonally immunomodulated peripheral immunization.
Infect
Immun 1996;64:1100-9. |
 |
[208] |
Casteels
K, Bouillon R, Waer M, Mathieu C. Immunomodulatory effects of 1, 25-dihydroxy-vitamin
D3. Curr Opin Nephrol Hypertens 1995;4:313-8. |
 |
[209] |
Branisteanu
DD, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R. Prevention of
murine experimental allergic encephalomyelitis: cooperative effects of
cyclosporine and
1á,
25-( OH) 2 D 3 . J Neuroimmunol 1995;61:151-60. |
 |
[210] |
Lemire
J, 1, 25-Dihydroxyvitamin D3--a hormone with immunomodulatory properties.
Z Rheumatol 2000;59 Suppl 1:24-7. |
 |
[211] |
Shedpure
M, Pati AK. The pineal gland: structural and functional diversity. Indian
J Exp Biol 1995;33:625-40. |
 |
[212] |
Roberts
JE. Visible light induced changes in the immune response through an eye-brain
mechanism (photoneuroimmunology). J Photochem Photobiol B Biol 1995;29:3-15. |
 |
[213] |
Morrey
KM, McLachlan JA, Serkin CS, Bakouche O. Activation of human monocytes
by the pineal hormone melatonin. J Immunol 1994;153:2671-80. |
 |
[214] |
DiStefano
A, Paulesu L. Inhibitory effect of melatonin on production of IFN - gamma
or TNF - alpha in peripheral blood mononuclear cells of some blood donors.
J Pineal Res 1994;17:164-169. |
 |
[215] |
Giordano
M, Vermeulen M, Palermo MS. Seasonal variations in antibody-dependent cellular
cytotoxicity regulation by melatonin. Int J Neurosci 1993;68:109-25. |
 |
[216] |
Mocchegiani
E, Bulian D, Santarelli L, Tibaldi A, Mozzioli M, Pierpaoli W, Fabris N.
The immuno-reconstituting effect of melatonin or pineal grafting and its
relation to zinc
pool
in aging mice. J Neuroimmunol 1994;53:189-201. |
 |
[217] |
Maestroni
GJ. MLT and the immune-hematopoietic system. Adv. Exp Med. Biol 1999;460:395-405. |
 |
[218] |
Nelson
RJ, Drazen DL. Melatonin mediates seasonal adjustments in immune function.
Reprod Nutr Dev 1999;May-Jun;39( 3):383-98. |
 |
[219] |
Levi-Montalcini
R. The nerve growth factor, its mode of action on sensory and sympathetic,nerve
cells. Harvey Lectures 1966;60:217-259. |
 |
[220] |
Pezzati
P, Stanisz AM, Marshall JS, Bienenstock J, Stead RH. Expression of nerve
growth factor receptor immunoreactivity on follicular dendritic cells from
human mucosa associated lymphoid tissues. Immunology 1992;76:485-490. |
 |
[221] |
Lomen-Hoerth
C, Shooter EM. Widespread neurotrophin receptor expression in the immune
system and other nonneuronal rat tissues. J Neurochem 1995;64:1780-9. |
 |
[222] |
Cosman
D. A family of ligands for the TNF receptor superfamily. Stem Cells Dayt
1994;12:440-55. |
 |
[223] |
Franklin
RA, Brodie C, Melamed I, Tereda N, Lucas JJ, Gelfand EW. Nerve growth factor
induces activation of MAP-kinase and p90 rsk in human B lymphocytes. J
Immunol 1995;154:4965-4972. |
 |
[224] |
Manning
PT, Russell JH, Simmons B, Johnson EM. Protection from guanethidine-induced
neuronal destruction by nerve growth factor: effect of NGF on immune function.
Brain Res 1985;340:61-69. |
 |
[225] |
Otten
U, Ehrhard P, Peck R. Nerve growth factor induces growth and differentiaton
of
human
B lymphocytes. Proc Natl Acad Sci USA 1989;86:10059-10063. |
 |
[226] |
Kimata
H, Yoshida A, Ishioka C, Kusunoki T, Hosoi S, Mikawa H. Nerve growth factor
specifically induces human IgG4 production. Eur J Immunol 1991;21:137-141. |
 |
[227] |
Brodie
C, Oshiba A, Renz H, Bradley K, Gelfand EW. Nerve growth factor and anti-CD40
provide opposite signals for the production of IgE in inteleukin-4-treated
lymphocytes. Eur J Immunol 1996;26:171-8. |
 |
[228] |
Santambrogio
L, Benedetti M, Chao MV, Muzaffar R, Kulig K, Gabellini N, Hochwald G.
Nerve growth factor production by lymphocytes. J Immunol 1994;153:4488-95. |
 |
[229] |
Leon
A, Buriani A, DalToso R, et al. Mast cells synthesize, store, and release
nerve growth factor. Proc Natl Acad Sci USA 1994;91:3739-43. |
 |
[230] |
Aloe
L, Levi-Montalcini R. Mast cells increase in tissues of neonatal rats injected
with the nerve growth factor. Brain Res 1977;133:358-366. |
 |
[231] |
Bohm
A, Aloe L, Levi-Montalcini R. Nerve growth factor enhances precocious differentiation
and numerical increase in mast cells in cultures of rat splenocytes. Acad
Naz Lineei 1986;80:1. |
 |
[232] |
Marshall
JS, Stead RH, McSharry C, Nielsen L, Bienenstock J. The role of mast cell
degranulation products in mast cell hyperplasia. I. Mechanism of action
of nerve growth factor. J Immunol 1990;144:1886-1892. |
 |
[233] |
Bischoff
SC, Dahinden CA. Effect of nerve growth factor on the release of inflammatory
mediators by mature human basophils. Blood 1992;79:2662-2669. |
 |
[234] |
Garaci
E, Caroleo MC, Aloe L, Aqaro S, Piacentini M, Costa N, Amendola A, Micera
A, Calio R, Perno CF, Levi-Montalcini R. Nerve growth factor is an autocrine
factor essential for the survival of macrophages infected with HIV. Proc
Nat Acad Sci USA 1999;96:14013-8. |
 |
[235] |
Gee
AP, Boyle MDP, Munger KL, Lawman MJ, Young M. Nerve growth factor: stimulation
of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci
USA
1983;80:7215-7218. |
 |
[236] |
Boyle
MDP, Lawman MJP, Gee AP, Young M. Nerve growth factor: a chemotactic factor
for polymorphonuclear leukocytes in vivo. J Immunol 1985;135:564-568. |
 |
[237] |
Banks
BEC, Vernon CA, Warner JA. Nerve growth factor has anti-inflammatory activity
in the rat hind paw oedema test. Neurosci Lett 1984;47:41-45. |
 |
[238] |
Amico-Roxas
M, Caruso A, Leone MG, Scifo R, Vanella A, Scapagnini U. Nerve growth factor
inhibits some acute experimental inflammations. Arch Int Pharmacodyn
Ther
1989;299:269-285. |
 |
[239] |
Braun
A, Appel E, Baruch R, Herz U, Botchkarev V, Paus R, Brodie C, Renz H. Role
of nerve growth factor in a mouse model of allergic airway inflammation
and asthma.
Eur
J Immunol 1998;Oct;28( 10):3240-51. |
 |
[240] |
Kerschensteiner
M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R,
Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle
H, Hohlfeld R. Activated human T cells, B cells, and monocytes produce
brain-derived neurotrophic factor in vitro and in inflammatory brain lesions:
a neuroprotective role of inflammation? J Exp Med 1999;Mar 1;189( 5):865-70. |
 |
[241] |
Besser
M, Wank R. Cutting edge: clonally restricted production of the neurotrophins
brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune
cells
and
Th1/ Th2-polarized expression of their receptors. Immunol 1999;Jun 1;162(
11):6303-6. |
 |
[242] |
Simone
MD, De Santis S, Vignetti E Papa G, Amadori S, Aloe L. Nerve growth factor:
a survey of activity on immune and hematopoietic cells. Hematol Oncol 1999;1:1-10. |
 |
[243] |
Hohlfeld
R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H. The neuroprotective
effect of inflammation: implications for the therapy of multiple sclerosis.
J Neuroimmunol 2000;Jul 24;107( 2):161-6. |
 |
[244] |
Reinshagen
M, Rohm H, Steinkamp M, Lieb K, Geerling I, Von Herbay A, Flamig G, Eysselein
VE, Adler G. Protective role of neurotrophins in experimental inflammation
of
the
rat gut. Gastroenterology. 2000;Aug;119( 2):368-76. |
 |
[245] |
Moalem
G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, Schwartz M. Production
of Neurotrophins by Activated T Cells: Implications for Neuroprotective
Autoimmunity.
J Autoimmun 2000;Nov;15( 3):331-345. |
 |
[246] |
Lord
GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates
the T-cell immune response and reverses starvation-induced immunosuppression.
Nature 1998; Aug 27;394( 6696):897-901. |
 |
[247] |
Bornstein
SR, Licinio J, Tauchnitz R, Engelmann L, Negrao AB, Gold P, Chrousos GP.
Plasma leptin levels are increased in survivors of acute sepsis: associated
loss of
diurnal
rhythm, in cortisol and leptin secretion. J Clin Endocrinol Metab 1998;Jan;83(
1): 280-3. |
 |
[248] |
Wauters
M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to
an endocrine mediator. Eur J Endocrinol 2000;Sept;143( 3):293-311. |
 |
[249] |
Hosoi
T, Okuma Y, Nomura Y. Expression of leptin receptors and induction of IL-1beta
transcript in glial cells. Biochem Biophys Res Commun 2000;Jun 24;273(
1): 312-5. |
 |
[250] |
Faggioni
R, Moser A, Feingold KR, Grunfeld C. Reduced leptin levels in starvation
increase susceptibility to endotoxic shock. Am J Pathol 2000;May;1 56(
5):1781-7. |
 |
[251] |
Matarese
G. Leptin and the immune system: how nutritional status influences the
immune response. Eur Cytokine Netw 2000;Mar;11( 1):7-14. |
 |
[252] |
Giovambattista
A, Chisari AN, Corro L, Gaillard RC, Spinedi E. Metabolic, neuroendocrine
and immune functions in basal conditions and during the acute-phase response
to endotoxic shock in undernourished rats. Neuroimmunomodulation 2000;7(
2): 92-8. |
 |
[253] |
Okamoto
S, Irie Y, Ishikawa I, Kimura K, Masayuki Saito. Central leptin suppresses
splenic lymphocyte functions through activation of the corticotropin-releasing
hormone - sympathetic nervous system. Brain Res 2000;Feb 7;855
(
1):192-7. |
 |
[254] |
Chautard
T, Spinedi E, Voirol M, Pralong FP, Gaillard RC. Role of glucocorticoids
in the response of the hypothalamo-corticotrope, immune and adipose systems
to repeated endotoxin administration. Neuroendocrinology 1999;May;69( 5):360-9. |
 |
[255] |
Torpy
DJ, Bornstein SR, Chrousos GP. Leptin and interleukin-6 in sepsis. Horm
Metab Res 1998; Dec;30 (12):726-9. |
 |
[256] |
Faggioni
R, Fantuzzi G, Gabay C, Moser A, Dinarello CA, Feingold KR, Grunfeld C.
Leptin deficiency enhances sensitivity to endotoxin-induced lethality.
Am J Physiol 1999;
Jan;
276( 1 Pt 2):R136-42. |
 |
[257] |
Takahashi
N, Waelput W, Guisez Y. Leptin is an endogenous protective protein against
the toxicity exerted by tumor necrosis factor. J Exp Med 1999;Jan 4;189(
1):207-12. |
 |
[258] |
Finck
BN, Kelley KW, Dantzer R, Johnson RW. In vivo and in vitro evidence for
the involvement of tumor necrosis factor-alpha in the induction of leptin
by lipopolysaccharide. Endocrinology 1998;May;139( 5): 2278-83. |
 |
[259] |
Loffreda
S, Yang SQ, Lin HZ, Karp CL, Brengman ML, Wang DJ, Klein AS, BulkleyGB,
Bao C, Noble PW, Lane MD, Diehl AM. Leptin regulates proinflammatory immune
responses. FASEB J 1998;Jan;12( 1):57-65. |
 |
[260] |
Fantuzzi
G, Faggioni R. Leptin in the regulation of immunity, inflammation, and
hematopoiesis. J Leukoc Biol 2000;Oct;68( 4):437-46. |
 |
[261] |
Barach
EM, Nowak RM, Lee TG, Tomlanovich MC. Epinephrine for treatment of anaphylactic
shock. JAMA. 1984;251( 16):2118-2122. |
 |
[262] |
Nelson
HS. Adrenergic therapy of bronchial asthma. J Allergy Clin Immunol 1986;77(
6):71-785. |
 |
[263] |
Livnat
S, Felten SY, Carlson DL, Bellinger FL, Felten DL. Involvement of peripheral
and central catecholamine systems in neural-immune interactions. J Neuroimmunol
1985;
10:5-30. |
 |
[264] |
Cross
RJ, Jackson JC, Brooks WH, Sparks DL, Markesbery WR, Roszman TL. Neuroimmunomodulation:
Impairment of humoral immune responsiveness by 6-hydroxy-dopamine treatment.
Immunology 1986;57( 1):145-152. |
 |
[265] |
Berczi
I, Nagy E. Neurohormonal control of cytokines during injury. In: Rothwell
NJ, Berkenbosch F, editors. Brain Control of Responses to Trauma. Cambridge
University
Press,
1994:32-107. |
 |
[266] |
Schauenstein
K, Rinner I, Felsner P, et al. The role of the adrenergic/ cholinergic
balance in the immune - neuroendocrine circuit. In: Berczi I, Szelenyi
J, editors. Advances in psychoneuroimmunology. New York, Plenum Press,
1994:349-356. |
 |
[267] |
Nagatomi
R, Kaifu T, Okutsu M, Zhang X, Kanemi O, Ohmori H. Modulation of the immune
system by the autonomic nervous system and its implication in immunological
changes
after training. Exerc Immunol Rev 2000;6:54-74. |
 |
[268] |
Szelenyi
J, Kiss JP, Vizi ES. Differential involvement of sympathetic nervous system
and immune system in the modulation of TNF-alpha production by alpha2-and
beta-adrenoceptors in mice. J Neuroimmunol 2000;Feb 1;103( 1):34-40. |
 |
[269] |
Bergmann
M, Gornikiewicz A, Sautner T, Waldmann E, Weber T, Mittlbock M, Roth E,
Fugger R. Attenuation of catecholamine-induced immunosuppression in whole
blood
from
patients with sepsis. Shock 1999 Dec;12( 6):421-7. |
 |
[270] |
Schauenstein
K, Rinner I, Felsner P, et al. The role of the adrenergic/ cholinergic
balance in the immune - neuroendocrine circuit. In: Berczi I, Szelenyi
J, editors. Advances in psychoneuroimmunology. New York, Plenum Press,
1994:349-356. |
 |
[271] |
Druce
HM, Wright RH, Kossoff D, Kaliner MA. Cholinergic nasal hyperreactivity
in atopic subjects. J Allergy Clin Immunol 1985;76:445-452. |
 |
[272] |
Coffey
RG, Hadden JW. Neurotransmitters, hormones, and cyclic nucleotides in lymphocyte
regulation. Fed Proc 1985;44( 1):112-117. |
 |
[273] |
Szelenyi
J, Ha NTH. Expression of cholinergic structure on lymphocytes. In: Berczi
I, Szelenyi J, editors. Advances in psychoneuroimmunology. New York, Plenum
Press,
1994:271-277. |
 |
[274] |
Payan
DG, McGillis JP, Renold FK, Mitsuhashi M, Goetzl EJ. The immunomodulating
properties of neuropeptides. In: Berczi I, Kovacs K, editors. Hormones
and immunity. Lancaster, England, MTP Press, 1987. |
 |
[275] |
Foreman
JC. Neuropeptides and the pathogenesis of allergy. Allergy 1987;42( 1):1-11. |
 |
[276] |
Shanahan
F, Lee TDG, Bienenstock J, Befus AD. Mast cell heterogeneity: Effect of
anti-allergic compounds on neuropeptide-induced histamine release. Int
Arch Allergy
Appl
Immunol 1986;80( 4):424-426. |
 |
[277] |
Jancso
G, Obal F Jr, Toth-Kasa I, Katona M, Husz S. The modulation of cutaneous
inflammatory reactions by peptide-containing sensory nerves. Int J Tissue
React 1985;
7(
6):449-457. |
 |
[278] |
Serra
M, Bazzoni F, Della Bianca V, Greskowiak M, Rossi F. Activation of human
neutrophils by substance P. Effect on oxidative metabolism, exocytosis,
cytosolic Ca 2+
concentration
and inositol phosphate formation. J Immunol 1988;141:2118-2124. |
 |
[279] |
Lotz
M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes:
Neural pathway in pathogenesis of arthritis. Science 1987;235( 4791):893-895. |
 |
[280] |
Hartung
HP, Heininger K, Schafer B, Toyka KV. Substance P and astrocytes: stimulation
of the cyclooxygenase pathway of arachidonic acid metabolism. Fed Am Soc
Exp Biol J 1988;2:48-51. |
 |
[281] |
Damonneville
M, Monte D, Auriault C, Capron A. The neuropeptide substance-P stimulates
the effector functions of platelets. Clin Exp Immunol 1990;81:346-351. |
 |
[282] |
Rameshar
P, Ganea D, Gascon P. Induction of IL-3 and granulocyte-macrophage colony-stimulating
factor by substance P in bone marrow cells is partially mediated through
the release of IL-1 and IL-6. J Immunol 1994;152:4044-4054. |
 |
[283] |
Mariott
I, Bost KL. IL-4 and IFN-gamma up-regulate substance P receptor expression
in murine peritoneal macrophages. J Immunol 2000;Jul 1;165( 1):182-91. |
 |
[284] |
Blum
AM, Metwali A, Kim-Miller M, Li J, Qadir K, Elliott DE, Lu B, Fabry Z,
Gerard N, Weinstock JV. The substance P receptor is necessary for a normal
granulomatous response in murine schistosomiasis mansoni. J Immunol 1999;May
15;162( 10):6080-5. |
 |
[285] |
Bienenstock
J. A model of neuroimmune communication: Mast cells and nerves. In: Neuroimmune
Biology: New foundation of Biology. Berczi I, Gorczynski R, editors.
Shannon,
Co. Clare, Ireland, Elsevier, 2001. |
 |
[286] |
Mullins
MW, Ciallella J, Rangnekar V, McGillis JP. Characterization of a calcitonin
gene-related peptide (CGRP) receptor on mouse bone marrow cells. Regul
Pept 1993;
49:65-72. |
 |
[287] |
Nong
YH, Titus RG, Ribeiro JMC, Remold HG. Peptides encoded by the calcitonin
gene inhibit macrophage function. J Immunol 1989;145:45-49. |
 |
[288] |
Wang
X, Fiscus RR, Tang Z, et al. CGRP in the serum of endotoxin-treated rats
suppresses lymphoproliferation. Brain Behav Immun 1994;8:282-292. |
 |
[289] |
Hosoi
J, Murphy GF, Egan CL, et al. Regulation of Langerhans cell function by
nerves containing calcitonin gene-related peptide. Nature 1993;363:159-63. |
 |
[290] |
Asahina
A, Hosoi J, Beissert S, Stratigos A, Granstein RD. Inhibition of the induction
of delayed-type and contact hypersensitivity by calcitonin gene-related
peptide. J Immunol
1995;154:3056-61. |
 |
[291] |
Millet
I, Phillips RJ, Sherwin RS, Ghosh S, Voll RE, Flavell RA, Vignery A, Rincon
M. Inhibition of NF-kappaB activity and enhancement of apoptosis by the
neuropeptide
calcitonin
gene-related peptide. J Biol Chem 2000;May 19;275( 20):15114-21. |
 |
[292] |
Wang
X, Xing L, Xing Y, Tang Y, Han C. Identification and characterization of
immuno-reactive calcitonin gene-related peptide from lymphocytes of the
rat. J Neuroimmunol 1999;Feb 1;94( 1-2):95-102. |
 |
[293] |
Streilein
JW, Alard P, Niizeki H. A new concept of skin-associated lymphoid tissue
(SALT): UVB light impaired cutaneous immunity reveals a prominent role
for cutaneous
nerves.
Keio J Med 1999;Mar; 48( 1):22-7. |
 |
[294] |
Foris
G, Gyimesi E, Komaromi I. The mechanism of antibody-dependent cellular
cytotoxicity stimulation by somatostatin in rat peritoneal macrophages.
Cell Immunol
1985;90(
1):217-225. |
 |
[295] |
Muscettola
M, Grasso G. Somatostatin and vasoactive intestinal peptide reduce interferon
gamma production by human peripheral blood mononuclear cells. Immunobiology.
1990;180:419-430. |
 |
[296] |
Church
MK, El-Lati S, Caulfield JP. Neuropeptide-induced secretion from human
skin mast cells. Int Arch Allergy Appl Immunol 1991;94:310-318. |
 |
[297] |
Bokum
AM, Hofl and LJ, van Hagen PM. Somatostatin and somatostatin receptors
in the immune system: a review. Eur Cytokine Netw 2000;Jun;11( 2):161-76. |
 |
[298] |
Szolcsanyi
J, Helyes Z, Oroszi G, Nemeth J, Pinter E. Release of somatostatin and
its role in the mediation of the anti-inflammatory effect induced by antidromic
stimulation of sensory fibres of rat sciatic nerve. Br J Pharmacol 1998;Mar;
23( 5):936-42. |
 |
[299] |
Ottaway
CA. In vitro alterations of receptors for vasoactive intestinal peptide
changes the in vivo localization of mouse T cells. J Exp Med 1984;160(
4):1054-1069. |
 |
[300] |
O'Dorisio
MS. Biochemical characteristics of receptors for vasoactive intestinal
polypeptidein nervous endocrine and immune systems. Fed Proc 1987;46( 1):192-195. |
 |
[301] |
Kimata
H, Fujimoto M. Vasoactive intestinal peptide specifi cally induces human
IgA1 and IgA2 production. Eur J Immunol 1994;24:2262-2265. |
 |
[302] |
Xin
Z, Tang H, Ganea D. Vasoactive intestinal peptide inhibits interleukin
(IL)-2 and IL-4 production in murine thymocytes activated via the TCR/
CD3 complex. J Neuroimmunol 1994;54:59-68. |
 |
[303] |
Boirivant
M, Fais S, Annibale B, Agostini D, Delle Fave G, Pallone F. Vasoactive
intestinal polypeptide modulates the in vitro immunoglobulin A production
by intestinal lamina propria lymphocytes. Gastroenterology. 1994;106:576-82. |
 |
[304] |
Delgado
M, Ganea D. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation
in macrophages by vasoactive intestinal peptide and pituitary adenylate
cyclase-activating polypeptide. J Immunol 2000;Sep 15;165( 6): 051-7. |
 |
[305] |
Sun
W, Tadmori I, Yang L, Delgado M, Ganea D. Vasoactive intestinal peptide
(VIP) inhibits TGF-beta1 production in murine macrophages. J Neuroimmunol
2000; Jul 10;
107(
1):88-99. |
 |
[306] |
Xin
Z, Sriram S, Vasoactive intestinal peptide inhibits IL-12 and nitric oxide
production in murine macrophages. J Neuroimmunol 1998; Aug 14;89( 1-2):206-12. |
 |
[307] |
Kawamura
N, Tamura H, Obana S, Wenner M, Ishikawa T, Nakata A, Yamamoto H. Differential
effects of neuropeptides on cytokine production by mouse helper T cell
subsets. Neuroimmunomodulation 1998;Jan-Apr;5( 1-2):9-15. |
 |
[308] |
Martinez
C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP. Vasoactive
intestinal peptide and pituitary adenylate cyclase-activating polypeptide
modulate endo-toxin-induced IL-6 production by murine peritoneal macrophages.
J Leukoc Biol 1998;May;63( 5):591-601. |
 |
[309] |
Tang
H, Sun L, Xin Z, Ganea D. Down-regulation of cytokine expression in murine
lymphocytes by PACAP and VIP. Ann N Y Acad Sci 1996; Dec 26;805:768-78. |
 |
[310] |
Martinez
C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP. VIP and
PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages:
in vitro and in vivo studies. J Neuroimmunol 1998;May 15;85( 2):155-67. |
 |
[311] |
Delgado
M, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating
polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by
inhibiting Fas ligand expression. J Immunol 2000; Feb 1;164( 3):1200-10. |
 |
[312] |
Taylor
AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide
contributes to the immunosuppresssive activity of normal aqueous humor.
J
Immunol 1994;153:1080-1086. |
 |
[313] |
Ferguson
TA, Fletcher S, Herndon J, Griffi th TS. Neuropeptides modulate immune
deviation induced via the anterior chamber of the eye. J Immunol 1995;155:1746-56. |
 |
[314] |
Lundeberg
L, Mutt V, Nordlind K. Inhibitory effect of vasoactive intestinal peptide
on the challenge phase of allergic contact dermatitis in humans. Acta Derm
Venereol
1999;May;79(
3):178-82. |
 |
[315] |
Frontiers
FB, editor. The Cytokine Network. In: Hames BD, Glover DM, series editors.
Oxford in Molecular Biology Series University Press, 2000. |
 |
[316] |
Grignani
G. Maiolo, Cytokines and hemostasis. A Haematologica 2000;Sept;85( 9):967-972. |
 |
[317] |
Warren
JL. Type I cytokines, interferons and their receptors. In: Paul WE, editor.
Fundamental Immunology, 4 th edition. Lippincott-Raven, 1999:741-74. |
 |
[318] |
Krauker
T, Vilcek J, Oppenheim JJ. Proinfl ammatory cytokines. In: Paul WE, editor.
Fundamental Immunology 4th edition. Lippincott-Raven, 1999:775-811. |
 |
[319] |
Mathison
RT, Davison JS, Befus AD. Neuroendocrine regulation of inflammation and
tissue repair by submandibular gland factors. Immunology Today 1994;14:527-532. |
 |
[320] |
Berczi
I, Chow DA, Sabbadini ER. Neuroimmunoregulation and natural immunity. Domestic
Anim Endocrin 1998;15:273-281. |
 |
[321] |
Sabbadini
ER, Berczi I. Immunoregulation by the salivary glands. Biomed Rev 1998;9:79-91. |
 |
[322] |
Befus
D et al. Immunomodulation by the submandibular gland. In: Berczi I, Gorczynski
R, editors. Neuroimmmune Biology: New Foundation of Biology. Shannon, Co.
Clare, Ireland, Elsevier, 2001. |
 |
[323] |
Sabbadini
et al. Immunoregulation by glandular kallikrein. In: Berczi I, Gorczynski
R, editors. Neuroimmmune Biology: New Foundation of Biology. Shannon, Co.
Clare,
Ireland,
Elsevier, 2001. |
 |
[324] |
Brandtzaeg
P, Farstad IN, Haraldsen G, Jahnsen FL. Cellular and molecular mechanisms
for induction of mucosal immunity. Dev Biol Stand 1998;92:93-108. |
 |
[325] |
Chen
YH, Weiner HL. Dose-dependent activation and deletion of antigen-specifi
c T cells following oral tolerance. Ann N Y Acad Sci 1996;Feb 13;778:111-21. |
 |
[326] |
Davison
J. The Salivary Gland Peptides: Their Role in Anaphylaxis and Lipopolysaccharide
(LPS)-Induced Inflammation. In: Berczi I, Gorczynski R, editors. Neuroimmmune
Biology: New Foundation of Biology.Shannon, Co. Clare, Ireland, Elsevier,
2001. |
 |
[327] |
McDermott
MR, Clark DA, Bienenstock J. Evidence for a common mucosal immunologic
system. II. Influence of the estrous cycle on B immunoblast migration into
genital and intestinal tissues. J Immunol 1980;Jun;124( 6):2536-9. |
 |
[328] |
Nagy
E, Berczi I. Pituitary dependence of bone marrow function. Brit J Haematol
1989;71:457-462. |
 |
[329] |
Berczi
I, Nagy E. Effects of hypophysectomy on immune function. In: Ader R, Felten
DL, Cohen N, editors. Psychoneuroimmunology II. Academic Press 1991:339-375. |
 |
[330] |
Bernard
C. Lecons sur les phenomenes de la vie communs aux animaux et aux vegetaux.
Balliere, Paris 1878. |
 |
[331] |
Berczi
I. Neurohormonal host defence in endotoxin shock Ann NY Acad Sci 840:787-802,
1998. |
 |
[332] |
Berczi
I, Bertok L, Chow D. Natural immunity and neuroimmune host defence..In:Ario
Conti, Georges J.M. Maestroni, Samuel M. McCann, Esther M. Sternberg, James
M. Lipton, Craig C., editors. Neuroimmunomodulation: Perspectives at the
New Millennium. Ann N Y Acad Sci 2000;917:248-57 |
 |
[333] |
Medzhitov
R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol
Rev 2000;Feb;173: 89-97. |
 |
[334] |
Berczi
I. The stress concept and neuroimmunoregulation in modern biology. Ann
NY Acad Sci 1998;851:3-12. |
 |
[335] |
Berczi
I. Neuroendocrine defence in endotoxin shock.
(A
review). Acta Microbiol Hun 1993;40( 4);265-302. |
 |
[336] |
Berczi
I, Nagy E. Neurohormonal control of cytokines during injury. In: Rothwell
NJ, Berkenbosch F, editors. Brain Control of Responses to Trauma. Cambridge
University
Press,
1994:32-107. |
 |
[337] |
Berczi
I. Neuroendocrine response to endotoxin. Ann NY Acad Sci 1998; 851: 411-415. |
 |
[338] |
Haeryfar
SMM, Berczi I. The thymus and the acute phase response. Mol Cell Biol 2001;47(1):145-56.
Review. |
 |
[339] |
Pittman
QJ, Chen X, Mouihate A, Martin S. Vasopressin-induced atipyresis. Sex-and
experience- dependent febrile response. Ann NY Acad Sci 1998;856:53-61. |
 |
[340] |
McEwen
BS. Allostasis, allostatic load, and the aging nervous system: role of
excitatory amino acids and excitotoxicity. Neurochem Res 2000;Oct;25( 9-10):1219-31. |
 |
[341] |
Anisman
H, Baines MG, Berczi I, Bernstein CN, Blennerhassett MG, Gorczynski RM,
Greenberg AH, Kisil FT, Mathison RD, Nagy E, Nance DM, Perdue MH, Pomerantz
DK, Sabbadini ER, Stanisz A, Warrington RJ. Neuroimmune mechanisms in health
and disease: 1. Health. Can Med Assoc J 1996;155( 7):867-874. |
 |
[342] |
Gorczinsky
R. Understanding classical conditioning of immune responses. In: Berczi
I, Gorczynski R, editors. Neuroimmune Biology: New Foundation of Biology.
Shannon, Co. Clare, Ireland, Elsevier, 2001. |
 |
[343] |
Pomerantz
D. Interactions Between the Immune and the Reproductive Systems. In: Berczi
I, Gorczynski R, editors. Neuroimmune Biology: New Foundation of Biology.
Shannon, Co. Clare, Ireland, Elsevier,2001. |
 |
[344] |
Luheshi
G. Leptin and Cytokines: Actions and Interactions in Fever and Appetite
Control. In: Berczi I, Gorczynski R, editors. Neuroimmune Biology: New
Foundation of Biology. Shannon, Co. Clare, Ireland, Elsevier, 2001. |
 |
[345] |
Baines
M. Olfactory Stimuli and Allo-Recognition. In: Berczi I, Gorczynski R,
editors. Neuroimmune Biology: New Foundation of Biology. Shannon, Co. Clare,
Ireland, Elsevier,2001. |
 |
[346] |
Berczi
I, Nagy E, Asa SL, Kovacs K. The influence of pituitary hormones on adjuvant
arthritis. Arthritis Rheum. 1984;27:682-688. |
 |
[347] |
Nagy
E, Friesen HG, Sehon AH, Berczi I. Immunomodulation in rats by transplantable
anterior pituitary tumors. Endocrinology 1985;16:1117-1122. |
 |
[348] |
Nagy
E, Berczi I. Immunomodulation by tamoxifen and pergolide. Immunopharmacology
1986;12:145-153. |
 |
[349] |
I.
Berczi I, Cosby H, Hunter T, Baragar F, McNeilly AS, Friesen HG. Decreased
bioactivity of circulating prolactin in patients with rheumatoid arthritis.
Brit J Rheum
1987;26:433-436. |
 |
[350] |
Nagy
E, Chalmers IM, Baragar FD, Friesen HG, Berczi I. Prolactin deficiency
in rheumatoid arthritis. J Rheumatol 1991;18:1662-1668. |
 |
[351] |
Ramachandra
RN, Sehon AH, Berczi I. Neuro-hormonal host defence in endotoxin shock.
Brain Behav Immun 1992;6:157-169. |
 |
[352] |
Baral
E, Nagy E, Berczi I. Target cells are sensitized for cytotoxic T lymphocyte
mediated destruction by estradiol and tamoxifen. Int J Cancer 1994;58:64-68. |
 |
[353] |
Baral
E, Nagy E, Berczi I. Modulation of natural killer cell mediated cytotoxicity
by tamoxifen and estradiol. Cancer 1995;75:591-599. |
 |
[354] |
Anisman
H., Baines MG, Berczi, Bernstein CN, Blennerhassett MG, Gorczynski RM,
Greenberg AH, Kisil FT, Mathison RD, Nagy E, Nance DM, Perdue MH, Pomerantz
DK, Sabbadini ER, Stanisz A., Warrington RJ. Neuroimmune mechanisms in
health and disease: 2. Disease. Can Med Assoc J 1996;155( 8):1075-1082. |
 |
[355] |
McCann
SM, Lipton JM, Sternberg EM, Chrousos GP, Gold PW, Smith CC, editors. Neuroimmunomodulation:
Molecular aspects, integrative systems, and clinical advances.
Ann
NY Acad Sci 1998;840. |
 |
[356] |
Csermely
P, editor. Stress of life, from molecules to man. Ann NY Acad Sci 851:
1998. |
 |
[357] |
Dickstein
J, Moldofsky H. Sleep, cytokines and immune function. Sleep Medicine Reviews
1999; 3( 3) (in press). |
 |
[358] |
S
Rivest, S Lacroix, L Vallieres, S Nadeau, J Zhang, N Laflamme. How the
blood talks to the brain parenchyma and the paraventricular nucleus of
the hypothalamus during systemic inflammatory and infectious stimuli. Proc
Soc Exp Biol Med 2000; 223: 22-38. |
 |
[359] |
Jacobs
LJ. Prolactin. In: Jaffe BM, Behrman HR, editors. Methods of Hormone Radioimmunoassay.
Academic Press 1979:199-222. |

|